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ABSTRACT 
Restenosis after percutaneous transluminal coronary angioplasty (PTCA) and allograft 
arteriosclerosis after organ transplantation limit the long-term survival of operated patients. 
The diseases are characterized by accumulation of smooth muscle cell (SMC)-like cells to the 
luminal side of the affected artery, their proliferation, migration, and extracellular matrix 
formation, which leads to the development of neointimal hyperplasia and constrictive vascular 
remodelling. Recent studies indicate that the proliferating neointimal SMCs derive from 
multipotent somatic stem cells (vascular progenitors), which are able to differentiate into 
vascular cells.  
The vasculoprotective properties of estrogens have been demonstrated in epidemiological and 
experimental studies, although some recent studies show contradictory evidence. Estrogen 
therapy is associated with increased risk for endometrial cancer, and may promote the growth 
of breast cancer, which limits its use in vasculoprotection. In addition to the classical estrogen 
receptor (ER) α, a novel ER, ERβ, was discovered in 1996, which greatly improved our 
understanding of estrogen’s signalling in different tissues during health and disease. The roles 
of the two receptors in the vascular wall are not completely understood. 
The aim of this study was to clarify the expression and regulation of the two ERs in different 
vasculoproliferative disorders, and to identify potential mechanisms behind estrogen’s 
vasculoprotective action, using rat denudation injury and cardiac transplantation models. The 
study shows substantial upregulation of ERβ in the vascular wall after mechanical and 
alloimmune injury, whereas ERα remains expressed at a low level only. ERβ is localized in 
the neointimal and medial SMCs of the arteries as well as in the veins, myocardium, and 
inflammatory cells of cardiac allografts, which suggests that these cells are targets for 
estrogen. Moreover, estrogen’s vasculoprotective properties in the injured vascular wall can be 
differentiated from its uterotrophic action with a ligand that shows higher binding affinity for 
ERβ. Thus, preferential targeting to ERβ might be useful when aiming to develop 
vasculoselective estrogens. Selective estrogen receptor modulators (SERM), which act as 
estrogen agonists in some tissues and are anti-estrogenic in others, preserve estrogen’s 
inhibitory effect on denudation injury-induced neointimal thickening by inhibiting vascular 
SMC-like cell proliferation and migration, in vivo and in vitro, and by enhancing 
reendothelialization. The impact of different SERMs on neointima formation varies depending 
on the timing of the treatment, where early timing appears to be particularly important.  
Finally, estradiol treatment after denudation injury downregulates the expression of insulin-
like growth factor 1, platelet-derived growth factor, and platelet-derived growth factor 
receptor α mRNA and protein, which is probably one of the mechanisms behind estrogen’s 
vasculoprotective actions. 
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INTRODUCTION 
Cardiovascular disease, caused by atherosclerosis, is the major cause of death in the Western 
world. Percutaneous transluminal coronary angioplasty (PTCA) is commonly used to relieve 
the symptoms of atherosclerosis. It is, however, complicated by restenosis in 30% to 50% of 
the patients (Holmes et al. 1984, Gruentzig et al. 1987, Nobuyoshi et al. 1988). Allograft 
arteriosclerosis is a major limitation to the long-term success rate in transplantation, and 
furthermore, about 50% of kidney grafts are lost to death with function - mainly for 
cardiovascular reasons (Lindholm et al. 1995). The pathogenesis of these vasculoproliferative 
disorders is still incompletely known and there are no effective therapies for their prevention.  
The development of atherosclerosis, restenosis, and allograft arteriosclerosis has been defined 
as a response to immunological, mechanical, or infectious injury to the arterial wall (Hayry et 
al. 1993, Ross 1993). Peculiar to the disorders is an inflammatory response followed by an 
influx of smooth muscle cell (SMC)-like cells to the luminal side of the affected artery; their 
proliferation, migration, and extracellular matrix formation, which leads to the development of 
neointimal hyperplasia and vascular remodelling. Recent studies suggest that the proliferating 
neointimal SMCs derive from multipotent somatic stem cells (vascular progenitors), which are 
able to differentiate into vascular cells (Hillebrands et al. 2000, Saiura et al. 2001). Peptide 
growth factors have been recognized as important regulators of SMC kinetics in the vascular 
wall (Cercek et al. 1991). 
The vasculoprotective properties of estrogens have been widely demonstrated in 
epidemiological and experimental studies (Farhat et al. 1996b, Mendelsohn and Karas 1999), 
although some recent prospective studies show conflicting data (Hulley et al. 1998, Rossouw 
et al. 2002). It was difficult to understand how estrogen therapy can - at the same time - induce 
proliferation in the endometrium and breast while being anti-proliferative in the cardiovascular 
system. A new era in the understanding of estrogen action began in 1996 with the discovery of 
a novel estrogen receptor (ER), ERβ, in addition to the classical ERα (Kuiper et al. 1996, 
Mosselman et al. 1996). Each of these receptors has distinct tissue distribution and regulation, 
which enables the development of tissue-selective estrogens. Although knock-out mouse 
studies suggest that either of the two ERs may mediate estrogen’s protective effects on the 
vascular wall (Iafrati et al. 1997, Karas et al. 1999, Karas et al. 2001), their contribution to the 
inhibition of neointimal thickening is still incompletely understood.    
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The purpose of this study was to investigate the expression and regulation of the two ERs in 
the mechanical or immunological injury-induced development of neointimal hyperplasia, to 
try to differentiate estrogen’s beneficial vasculoprotective properties from its gender-related 
side-effects with ER subtype-selective estrogen, and to try to elucidate the mechanisms behind 
estrogen’s vasculoprotective action. 
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REVIEW OF THE LITERATURE 
1. Vasculoproliferative disorders 
1.1. Atherosclerosis 
Atherosclerosis is defined as a chronic inflammatory fibroproliferative disorder which causes 
narrowing of the affected arteries and produces ischemia of tissues perfused through these 
arteries (Ross 1986, Ross 1993, Ross 1999). It is the major cause of cerebral and myocardial 
infarction, ischemia of the intestines and lower extremities, and accounts for more than half of 
deaths in the Western world.  
The early lesions in atherosclerosis consist of cholesterol-filled macrophages, ‘foam cells’, in 
the subendothelium of the arterial wall (Ross 1993, Ross 1999). These fatty streaks may be 
found in the aorta already during the first decade of life, and they are precursors to the more 
advanced lesions, called ‘fibrous lesions’. Characteristic to such lesions is a ‘fibrous cap’ 
consisting of SMC and extracellular matrix (ECM), and a lipid-rich necrotic core. Advanced 
lesions may also become calcified and ulcerated, or complicated with hemorrhage. The most 
important clinical complication in an atherosclerotic artery is acute occlusion due to the 
formation of a thrombus, usually caused by a rupture of the plaque, resulting in myocardial 
infarction or stroke. 
Atherosclerosis is a multifactorial disease. Well-recognized risk factors associated with the 
disease include age, male sex, familial predisposition, hyperlipidemia, hypertension, diabetes, 
smoking, and lack of exercise. More recently, other possible risk factors have been identified, 
such as elevated levels of C-reactive protein (CRP), homocysteine, fibrinogen, plasminogen 
activator inhibitor (PAI) I, and apolipoprotein(a) (Grainger et al. 1994, Thompson et al. 1995, 
Graham et al. 1997, Nygard et al. 1997). Also, several studies indicate that infectious agents 
like Chlamydia pneumoniae (Saikku et al. 1988, Kuo et al. 1993) and cytomegalovirus (CMV) 
(Sorlie et al. 1994, Nieto et al. 1996) are associated with an increased risk for atherosclerosis.   
Changes in lifestyle are essential for the prevention of atherosclerosis. Moreover, clinical trials 
have demonstrated the benefits of lipid-lowering therapies (Shepherd et al. 1995, Sacks et al. 
1996, Downs et al. 1998) and blood pressure reduction (Hansson et al. 1998) in primary and 
15  
secondary prevention of cardiovascular disease. Although several pilot studies have shown 
positive effects of antibiotic treatment against chlamydia pneumoniae in the secondary 
prevention of cardiovascular events (Gupta et al. 1997, Gurfinkel et al. 1997), no large 
randomized trials have so far confirmed those findings (Cercek et al. 2003, O'Connor et al. 
2003). 
1.2. Restenosis  
Percutaneous transluminal coronary angioplasty (PTCA), first performed in 1977 (Gruntzig et 
al. 1979), has become a well-established technique for myocardial revascularization to relieve 
symptoms of coronary heart disease (CHD). However, restenosis, defined as reocclusion of 
the operated artery, remains a remarkable problem after the operation. Restenosis occurs in 
about 30%-50% of the patients within 3 to 6 months after successful intervention (Holmes et 
al. 1984, Gruentzig et al. 1987, Nobuyoshi et al. 1988), and often leads to reoperation.  
Characteristic to restenosis is the accumulation of vascular SMC to the luminal side of the 
artery, their proliferation and migration, and extracellular matrix formation, which results in 
neointimal hyperplasia (Libby et al. 1992, Haudenschild 1993, Casscells et al. 1994). Negative 
remodelling, or constriction of the artery, also plays a crucial role in the process (Lafont et al. 
1995, Mintz et al. 1996). Reconstitution of the endothelium limits the growth of the neointima 
with time (Fishman et al. 1975, Clowes et al. 1978, Haudenschild and Schwartz 1979). 
It is difficult to predict reocclusion of the artery from clinical variables and current data on the 
related risk factors are inconsistent. Certain patient-related risk factors, such as age, diabetes, 
hypertension, severe angina, genetic predisposition, and elevated fibrinogen and homocysteine 
levels, have, however, been associated with restenosis (Rensing et al. 1993, Weintraub et al. 
1993, Montalescot et al. 1995, van Bockxmeer et al. 1995, Schnyder et al. 2002). The most 
important predictive lesion characteristics are small vessel diameter, long lesion length, and 
very small lumen diameter before and after the operation (Rensing et al. 1993, Foley et al. 
1994) 
There is currently no effective treatment for restenosis. Several pharmacological approaches, 
e.g., with angiotensin converting enzyme (ACE) inhibitors, β-blockers, and 
methylprednisolone, have been attempted but none of them has been effective in preventing 
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the disease (Pepine et al. 1990, Faxon 1995, Serruys et al. 2000). By the year 2002, of the 37 
compounds tested, only 4 demonstrated efficacy in randomized placebo-controlled studies 
(Table 1). Metal intracoronary stents, which are placed at the point of the atherosclerotic 
occlusion during PTCA, were introduced during the 1990’s (Serruys et al. 1991, Fischman et 
al. 1994). The stent maintains the vessel lumen diameter, and thus prevents elastic recoil and 
negative remodelling; however, excessive neointimal hyperplasia, or in-stent restenosis 
(Virmani and Farb 1999), remains a significant problem affecting 10%-30% of patients with 
stent. Drug-eluting stents, which deliver the medication directly to the site of injury, have so 
far proven efficacious with minimal in-stent restenosis during a 6 to 12 month follow-up 
(Sousa et al. 2001a, Sousa et al. 2001b, Morice et al. 2002, Grube et al. 2003). Their long-term 
efficacy and safety are still to be investigated.  
Table 1. Clinical experience in the prevention of restenosis 
Compound Target Efficacy References 
    
Linsidomine (PTCA) NO donor 45% vs. 38% (p=0.03)* Lablanche et al. 1997 
Trapidil (PTCA) PDGF antagonist 40% vs. 21% (p=0.01)* Okamoto et al. 1992, 
Maresta et al. 1994 
Angiopeptin (PTCA) Somatostatin receptors 2, 3, 5 40% vs. 12% (p=0.003)* Eriksen et al. 1995 
Rapamycin (stent) mTOR 27% vs. 0% (p=0.001)* Morice et al. 2002 
    
* 6-month or ** 3-month endoscopic follow-up 
1.3. Transplant arteriosclerosis and accelerated recipient atherosclerosis 
Although the development of new immunosuppressive drugs has dramatically improved the 
short-term success rate in transplantation, long-term survival (after one post-operative year) 
has not improved as much, and chronic allograft rejection remains the leading cause of late 
graft failure. Furthermore, in renal transplantation, about half of the late failures are due to 
recipient death with a functioning graft, mainly because of cardiovascular reasons (accelerated 
atherosclerosis) (Lindholm et al. 1995, Kasiske et al. 1996).  
Chronic rejection is histologically characterized as persistent perivascular inflammation, 
fibrosis, and arteriosclerosis of all intra-graft arteries to the level of arterioli. Unlike in 
common atherosclerosis, the vascular lesions in transplant arteriosclerosis are often diffuse 
and concentric; not focal and eccentric. They are composed mainly of α-actin expressing SMC 
and extracellular matrix; calcifications are usually not seen (Johnson et al. 1991). These 
common histological changes in all transplants are accompanied with organ-specific 
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alterations, such as basement membrane thickening, glomerular sclerosis, and tubular atrophy 
in the kidney (Isoniemi et al. 1992). 
The etiology of chronic rejection is multifactorial. Several factors have been shown to 
influence the long-term outcome of the graft, and they are usually divided into alloantigen-
related, alloantigen-unrelated, and infectious factors. Alloantigen-related factors include 
histoincompatibility, insufficient immunosuppression, presence of anti-HLA antibodies (‘pre-
sensitisation’), and acute rejection (Suciu-Foca et al. 1991, Opelz 1992, Almond et al. 1993, 
Basadonna et al. 1993, Yilmaz and Hayry 1993). Alloantigen-unrelated factors include very 
young or very old donor age, ischemia-reperfusion injury, hyperlipidemia, hypertension, 
diabetes, and donor-recipient size-incompatibility (Cheigh et al. 1989, Cho et al. 1989, Lim 
and Terasaki 1991, Yuge and Cecka 1991, Heemann et al. 1994, Isoniemi et al. 1994, Dimeny 
et al. 1995). Finally, infectious factors, such as CMV infection, have been associated with the 
development of graft failure, allograft arteriosclerosis, and death after transplantation  
(O'Grady et al. 1988, Grattan et al. 1989, McDonald et al. 1989). 
At the moment, there is no specific therapy for chronic rejection. Only preventive measures 
are available and their aim is to intervene with the potential risk factors in the disease process. 
As mentioned above, the development of immunosuppressive drugs, especially the 
introduction of cyclosporine in the late 70’s (Calne et al. 1978), dramatically decreased the 
incidence of acute rejection and improved the early survival after transplantation. In the 
1990’s, new drugs have been developed, including mycophenolate mofetil, tacrolimus, 
sirolimus, and everolimus. Their long-term effects in humans are still under investigation. 
However, everolimus has been shown to significantly reduce transplant arteriosclerosis in 
cardiac allograft recipients (Eisen et al. 2003). Ganciclovir prophylaxis has been shown to 
inhibit allograft arteriosclerosis in CMV-infected rats (Lemstrom et al. 1994) as does the 
combination of ganciclovir and CMV hyperimmune globulin in seronegative recipients of a 
CMV seropositive heart transplant (Valantine et al. 2001). Statin-therapy also reduced the 
incidence of rejection episodes and the progression of cardiac allograft vasculopathy 
(Kobashigawa et al. 1995). Anti-hypertensive treatment with calcium channel blockers and 
ACE inhibitors had beneficial effects on allograft vasculopathy in the rat (Atkinson et al. 
1993, Kobayashi et al. 1993, Paul et al. 1994). Similar results were achieved also in a small 
clinical study (Mehra et al. 1995). 
18  
 
Figure 1. Histological cross sections of a coronary artery with significant luminal obstruction caused by (A) 
atherosclerosis; (B) in-stent-restenosis after PTCA and stent implantation; and (C) cardiac allograft 
vasculopathy. The arrow indicates the hole where the stent wire has been removed. (A, B), Braunwald Medical 
Library, with permission of Current medicine, Philadelphia, PA; (C) Libby and Pober. Immunity 2001;14:387-
397, with permission of  Elsevier Inc., New York, NY.  
Finally, patient death with a functioning graft is the major cause of late graft failure after 
kidney transplantation, and accelerated atherosclerosis in the recipient accounts for about half 
of these deaths (Lindholm et al. 1995, Kasiske et al. 1996). Certain known risk factors of 
common atherosclerosis, such as age, sex, diabetes, smoking, and hypertension, are also 
associated with accelerated atherosclerosis in the recipient (Kasiske 1988). In addition, it 
seems that the inflammatory response evoked in the recipient may contribute to the 
development of atherosclerotic lesions. This is similar to several autoimmune diseases, 
including systemic lupus erythematosus and rheumatoid arthritis, in which chronic 
inflammation and immune dysregulation are linked to accelerated coronary artery disease at 
young age (Manzi et al. 1997, Esdaile et al. 2001).  
2. Pathogenesis of the vasculoproliferative disorders  
2.1. The response-to-injury theory 
Vascular response to injury is a common denominator in all the vasculoproliferative disorders 
described above. The response-to-injury theory, originally formulated and later modified by 
Russel Ross (Ross and Glomset 1973, Ross 1986, Ross 1993), suggests that the development 
of the lesion is a protective inflammatory-fibroproliferative response to different forms of 
injury to the arterial wall. Although originally established for atherosclerosis, it can also be 
applied to chronic rejection (Hayry et al. 1993, Libby and Pober 2001) and restenosis (Libby 
et al. 1992, Casscells et al. 1994), since the pathophysiological mechanisms following vascular 
injury are presumed not to be too distant. 
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2.2. Inflammation 
Whether the vascular injury is mechanical, immunological, or infectious in origin, it initially 
leads to an inflammatory response. The injured endothelium is triggered to express numerous 
pro-inflammatory molecules, which mediate the entry of the inflammatory cells, mainly 
macrophages and lymphocytes, to the vessel wall. Selectins mediate the rolling of leukocytes 
along the endothelium by binding to carbohydrate ligands on the cells (Frenette and Wagner 
1996, Frenette and Wagner 1997, Dong et al. 1998), and they are upregulated in endothelial 
cells overlying human atheromas (O'Brien et al. 1993), in restenosis (Serrano et al. 1997, 
Yasukawa et al. 1997), as well as in allograft arteriosclerosis (Koskinen and Lemstrom 1997). 
Further adhesion of leukocytes to the endothelium is mediated by vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). Blocking the action 
of selectins, VCAM-1, and ICAM-1 has been shown to protect against the development of 
atherosclerosis, restenosis, or allograft arteriosclerosis (Sligh et al. 1993, Barron et al. 1997, 
Suzuki et al. 1997, Yasukawa et al. 1997, Collins et al. 2000).  
Once leukocytes are adherent to the endothelium, they migrate into the vascular wall in 
response to the influence of different chemoattractant proteins, such as monocyte chemotactic 
protein-1 (MCP-1) (Gu et al. 1998). The activated inflammatory cells replicate and secrete 
cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor α (TNF-α), which, in turn, 
stimulate endothelial cells (EC) and vascular SMCs (Hancock et al. 1994). These cytokines 
are also produced by the ECs and SMCs (Moyer et al. 1991, Galea et al. 1996). Recent studies 
also support a role for interactions between CD40, expressed on lymphocytes, macrophages, 
ECs, and SMCs, and its ligand (CD40L) in the development of advanced atherosclerotic 
lesions, as the binding of CD40 to CD40L results in the production of cytokines, matrix-
degrading proteases, and adhesion molecules (Schonbeck et al. 2000). Cytokine induction 
leads to increased expression of pro-inflammatory molecules, increased leukocyte 
extravasation, and increased inflammation - generating a vicious circle.  
Finally, SMC migration and proliferation within the arterial intima is induced by growth 
factors and vasoactive peptides released by the activated leukocytes. SMCs express receptors 
for these ligands, and also synthesize them, which results in persistent paracrine and autocrine 
proliferation (Raines et al. 1989, Battegay et al. 1990) Finally, these inflammatory-
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fibroproliferative cascades culminate in the advanced fibrous lesions in atherosclerosis, 
thickened neointima in restenosis, or vascular lesions in transplant arteriosclerosis.  
2.3. Peptide growth factors 
Peptide growth factors have an important role in the development of fibroproliferative 
vascular lesions (Cercek et al. 1991). Arterial SMC have been shown to synthesize numerous 
growth factors in vitro (Nilsson et al. 1985, Crowley et al. 1995). Several growth factors, such 
as insulin-like growth factor 1 (IGF-1) (Cercek et al. 1990), epidermal growth factor (EGF) 
(Miano et al. 1993), platelet-derived growth factor (PDGF) A and B (Majesky et al. 1990, 
Miano et al. 1993), and transforming growth factor β1 (TGF- β1) (Majesky et al. 1991) are 
upregulated in the vascular wall after endothelial injury in vivo. Furthermore, inhibition of 
PDGF (Ferns et al. 1991b, Myllarniemi et al. 1997, Sihvola et al. 1999, Noiseux et al. 2000), 
IGF (Hayry et al. 1995), and basic fibroblast growth factor (bFGF) (Lindner and Reidy 1991) 
signalling with antibodies, peptidomimetics, antisense treatment, or tyrosine kinase inhibitors 
have been shown to prevent injury-induced neointimal hyperplasia and allograft 
arteriosclerosis - further emphasizing their role in these disease processes. In this thesis, I have 
focused mainly on the regulation of PDGF and IGF-1 in the vascular response-to-injury. 
2.4. Platelet-derived growth factor (PDGF) 
PDGF is known as the most potent SMC chemoattractant and mitogen. It is also important in 
embryonic vascular development (Leveen et al. 1994, Soriano 1994) and has angiogenic 
properties (Battegay et al. 1994). Although originally discovered as a product of platelets 
(Antoniades et al. 1979), PDGF has thereafter been shown to originate from several other cell 
types, including vascular ECs and SMCs  (DiCorleto and Bowen-Pope 1983, Nilsson et al. 
1985). Four PDGF genes have been identified; the classical PDGF-A and PDGF-B, and the 
novel PDGF-C and PDGF-D. PDGF ligands consist of disulfide-linked polypeptide dimers. 
PDGF-A and PDGF-B form both homo- and heterodimers (PDGF-AA, -BB, or -AB) (Ross et 
al. 1986), while the novel PDGFs exist only as homodimers (PDGF-CC and PDGF-DD) (Li et 
al. 2000, Bergsten et al. 2001). PDGF ligands act via PDGF-receptors (PDGF-Rα and -Rβ) 
(Heldin and Westermark 1999). PDGF-Rα binds PDGF-A, PDGF-B, and PDGF-C, whereas 
PDGF-Rβ binds only PDGF-B and PDGF-D (Hart et al. 1988, Claesson-Welsh et al. 1989, Li 
et al. 2000, Bergsten et al. 2001). PDGF-receptors are protein tyrosine kinase receptors. Upon 
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ligand binding, the receptors dimerize, which results in autophosphorylation of the tyrosine 
residues between the two receptors and a biological response.  
PDGF and its receptors are detected in normal human arteries (Barrett and Benditt 1988) and 
they are upregulated in human atherosclerotic arteries (Barrett and Benditt 1988, Libby et al. 
1988, Wilcox et al. 1988), coronary arteries after PTCA (Tanizawa et al. 1996, Ueda et al. 
1996), and transplant vasculopathy (Zhao et al. 1995), as well as in several experimental 
models of vascular injury (Majesky et al. 1990, Uchida et al. 1996, Lemstrom and Koskinen 
1997). In vitro, PDGF-A mainly acts as a mitogen for vascular cells, and PDGF-Rα, when 
activated by ligand binding, stimulates proliferation, but not migration, of vascular SMC 
(Koyama et al. 1994). PDGF-B, on the other hand, is considered as the most potent SMC 
mitogen and chemoattractant (Grotendorst et al. 1982, Ross et al. 1986). Infusion of PDGF-
BB into rats after denudation injury (Jawien et al. 1992) or transfer of the recombinant PDGF-
B gene into porcrine arteries (Nabel et al. 1993) induced intimal hyperplasia in vivo. On the 
contrary, neointimal thickening was inhibited by a neutralizing PDGF antibody (Ferns et al. 
1991b) as well as by antisense treatment against PDGF-Rβ (Noiseux et al. 2000). 
The roles of PDGF-C and PDGF-D in the vasculature are being explored. So far, both ligands 
have been demonstrated to stimulate human coronary artery SMC proliferation in vitro (Uutela 
et al. 2001). 
2.5. Insulin-like growth factor-1 (IGF-1) 
IGF-1 has numerous physiological actions from embryonic development (Baker et al. 1993) to 
metabolic functions (Jacob et al. 1989), and as a mediator of the effects of growth hormone. It 
is also an important regulator of proliferation and migration of vascular cells, including 
fibroblasts and SMC (Cercek et al. 1990, Ferns et al. 1991a, Bornfeldt et al. 1994). The actions 
of IGF-1 are mediated via a specific membrane tyrosine kinase receptor, IGF-1R (LeRoith et 
al. 1995), which has been detected on SMC (Pfeifle and Ditschuneit 1983), inflammatory cells 
(Hochberg et al. 1992), and ECs (Bar and Boes 1984). The bioactivity of IGF-1 is, 
furthermore, regulated by six different IGF binding proteins (IGFBP) (Shimasaki and Ling 
1991).  
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IGF-1 is expressed in normal SMCs of rat aorta, localizing predominantly to medial SMC 
(Delafontaine et al. 1991, Khorsandi et al. 1992), and it is upregulated markedly after vascular 
injury in rat (Cercek et al. 1990) and in human coronary atherectomy specimens (Grant et al. 
1996). IGF-1 is also synthesized by macrophages (Nagaoka et al. 1990) and ECs 
(Delafontaine 1995). IGF-1 alone appears to be a poor mitogen for vascular SMC (Ferns et al. 
1991a). However, IGF-1 is considered as an important progression factor for PDGF, in other 
words, autocrine or paracrine production of IGF-1 and a functional IGF-1R are suggested to 
be necessary for PDGF to induce its full mitogenic effects on SMCs and fibroblasts 
(Clemmons and Van Wyk 1985, Sara and Hall 1990, Miura et al. 1994, DeAngelis et al. 
1995).  
2.6. Vascular precursor cells 
Traditionally, vascular SMCs were believed to exist in two different phenotypic states, the 
contractile and the secretory state (Campbell and Campbell 1990, Thyberg et al. 1990). SMCs 
within a normal artery were described as contractile, as they were filled with myofilaments but 
contained a poorly developed Golgi apparatus and rough endoplasmic reticulum. In response 
to the action of different cytokines and growth factors in the injured artery, these ‘normal’ 
SMC were thought to undergo a phenotypic change into a secretory or synthetic phenotype. 
This phenotype had histologically an abundant rough endoplasmic reticulum and Golgi 
apparatus, but few or no myofilaments. The secretory SMCs were capable of producing a 
number of ECM proteins and matrix metalloproteinases, that enabled their migration into the 
intima (Bendeck et al. 1994, Galis et al. 1995, Bendeck et al. 1996), as well as growth factors.  
Until recently, it was also considered that the SMCs accumulating in the intima migrated there 
only from the medial layer. Recent data, however, suggest that the proliferating neointimal 
SMC in transplant vasculopathy, in experimental atherosclerosis, and after mechanical arterial 
injury derive mainly from circulating somatic stem cells (vascular progenitors), partly of bone 
marrow origin, that at least in vitro are capable of differentiating into endothelial and smooth 
muscle cells (Hillebrands et al. 2000, Hillebrands et al. 2001, Saiura et al. 2001, Shimizu et al. 
2001, Hillebrands et al. 2002, Hu et al. 2002, Sata et al. 2002). The route of vascular 
progenitors to the vessel wall is not clear. Some studies suggest that adventitial activation 
contributes significantly to neointima formation (Shi et al. 1996a, Shi et al. 1996b, Frosen et 
al. 2001) while others support a luminal route to the vascular wall (Matsumoto et al. 2003). 
23  
3. Estrogens  
3.1. Introduction to natural estrogens 
Estrogens are steroid hormones that regulate the growth, differentiation, and function of 
several tissues in the human body. The female reproductive system, including mammary 
gland, uterus, placenta, and vagina, is considered as a traditional estrogen target tissue. In 
addition, estrogens play an important role in the male reproductive system and many non-
reproductive tissues, such as the cardiovascular system, bone, and the central nervous system.  
In premenopausal women, 95% of the estrogens are synthesized in the granulosa cells of the 
ovary (Richards and Hedin 1988). The most important natural estrogen in premenopausal 
women is 17β-estradiol (E2) (Fig. 2). The level of E2 production depends on the time of the 
menstrual cycle, and serum concentrations of E2 are approximately 40-360 pmol/l in the 
follicular phase, 630-2800 in the midcycle, and 700-1200 pmol/l in the luteal phase of the 
menstrual cycle, and up to 70,000 pmol/L during pregnancy (O'Malley and Strott 1999). In the 
plasma, E2 is bound predominantly to albumin and sex hormone-binding globulin (SHBG) 
(Dunn et al. 1981) and the remaining free fraction is available for uptake by estrogen target 
tissues. Estradiol is mainly excreted in the urine, and the principal metabolites are estriol (E3) 
and catechol estrogens (2- and 4-hydroxy-estrone), which also have numerous biological 
actions (Dubey et al. 2004).   
During the menopause, the ovaries cease to secrete E2, and thereafter, estrogens are mainly 
derived from androgens, such as testosterone, androstenedione, and dehydroepiandrosterone, 
through peripheral aromatization in mesenchymal cells of the adipose tissue, the osteoblasts 
and chondrocytes of bone, the vascular endothelium and SMCs as well as the brain (Grodin et 
al. 1973, Simpson 2003). In postmenopausal women estrone (E1), which has a biologic 
potency of approximately one third that of estradiol, is the predominant estrogen. In males, 
estrogens are produced by the testes, adrenals, and adipose tissue, and the levels of E2 are 
similar to those of postmenopausal women (30-200 pmol/L) (O'Malley and Strott 1999). 
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Figure 2. Molecular structure of 17β-estradiol 
3.2. The nuclear receptor superfamily 
Most of the effects of estrogen are mediated by estrogen receptors (ER). ERs belong to the 
nuclear receptor (NR) gene superfamily, which also includes receptors for other steroid 
hormones, thyroid hormones, vitamin A and D, retinoids, as well as several ‘orphan 
receptors’, which are receptors interacting with unknown compounds (Evans 1988, Laudet et 
al. 1992, Mangelsdorf et al. 1995).  
The NR superfamily has an evolutionarily and functionally conserved structure (Kumar et al. 
1987, Laudet et al. 1992). The receptors consist of six functional domains: an N-terminal 
domain (A/B domain), a DNA-binding domain (DBD; C domain), a hinge region (D domain), 
and a ligand-binding domain (LBD; E/F domain). The A/B domain, which usually has the 
lowest degree of sequence similarity among the NR family members, contains a ligand-
independent transactivation function (AF-1) domain that contributes to transcriptional activity 
interacting with other transcription factors and coregulatory proteins, and it acts in a promoter- 
and cell-specific fashion (Tora et al. 1989, Kraus et al. 1995, McInerney and 
Katzenellenbogen 1996, McInerney et al. 1996). The DBD is the most conserved region 
among the NR superfamily. It contains two zinc finger motifs, and it is involved in DNA 
binding, receptor dimerization, and transactivation of genes (Freedman 1992, Glass 1994). 
The D domain serves as a hinge between DBD and LBD, and its actions are less well 
characterized. LBD is critical in the binding of NR agonists and antagonists as well as 
dimerization, cofactor binding, ligand-dependent transactivation, and nuclear localization, and 
it is relatively well conserved among nuclear receptors (Kumar et al. 1987, Carson-Jurica et al. 
1990). A second activation function (AF-2) domain is located in the LBD and it interacts with 
coregulatory proteins (Kumar et al. 1987, Webster et al. 1988, Tora et al. 1989). 
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3.3. Nuclear receptor activation and signal transduction 
Nuclear receptors act as ligand-activated transcription factors. In short, their activation 
involves diffusion of the ligand to the target cell (Rao 1981) and binding of the ligand to the 
receptor in the cytoplasm or the nucleus. Ligand binding detaches the receptor from inhibitory 
heat shock proteins (hsp) and induces a conformational change in the structure of the receptor, 
which facilitates receptor dimerization, nuclear translocation, and the binding of the ligand-
receptor complex to specific DNA elements in the target genes (Tsai and O'Malley 1994). This 
results in the regulation of the gene transcription through interaction with coregulatory 
proteins (coactivators or corepressors) and the transcription machinery (Fig. 3). Receptor 
activation is also influenced by phosphorylation (Kuiper and Brinkmann 1994). 
Furthermore, nuclear receptors have been shown to regulate the transcription of some genes 
that do not contain their classical response elements. For example, estrogen stimulates several 
genes through interactions with other transcription factors, such as AP-1 or Sp1, that bind to 
their cognate DNA binding sites (Webb et al. 1995, Saville et al. 2000). Estradiol can also 
inhibit the expression of target genes through negative regulation of transcription factors, 
including nuclear factor-κB (Ray et al. 1994, Galien and Garcia 1997). 
On the other hand, nuclear receptors can also be activated in a ligand-independent fashion, by 
signals originating from the cell surface. Estrogen receptors are activated in the absence of 
ligand by activators of protein kinase A, protein kinase C, dopamine, and growth factors, such 
as EGF and IGF-1 (Power et al. 1991, Aronica and Katzenellenbogen 1993, Smith et al. 1993, 
Kato et al. 1995, Bunone et al. 1996, Weigel 1996, Lahooti et al. 1998).  
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Figure 3. The classical pathway of estrogen receptor action in the cell. Estradiol (E2) diffuses into the cell and 
binds to the estrogen receptor (ER) in the cytoplasm or the nucleus. ER undergoes a conformational change and 
dissociates from heat shock proteins (hsp), such as hsp90. The ligand-receptor complex dimerizes and interacts 
with specific DNA elements in the nucleus, such as estrogen response element (ERE), located in the promotor 
region of the target genes, as well as with coregulatory proteins. This results in the up- or downregulation of the 
gene transcription and an estrogenic response in the cell. 
3.4. Estrogen receptors 
The existence of the estrogen receptor was recognized about 40 years ago by the observation 
that uterus and vagina specifically bound estradiol (Jensen and Jacobson 1962). The receptor 
was cloned 25 years later (Green et al. 1986, Greene et al. 1986), and thereafter, the ER was 
believed to be the only mediator of estrogen’s action in its target tissues. Surprisingly, 
however, ER knock-out mice (ERKO) appeared healthy, except for problems in their fertility 
(Lubahn et al. 1993, Korach et al. 1996), and furthermore, mutation of the estrogen receptor 
gene in man was not lethal (Smith et al. 1994). Then, in 1996 a novel ER was cloned in the rat 
(Kuiper et al. 1996), man (Mosselman et al. 1996), and mouse (Tremblay et al. 1997), and it 
was named ERβ to distinguish it from the classical receptor, which was renamed ERα. In 
many respects, the finding of this new ER opened fresh vistas for the understanding of 
estrogen receptor signalling.  
Both ERα and ERβ bind E2 with high affinity (Kuiper et al. 1997) and they bind to the 
classical estrogen response elements (ERE) with similar affinities (Kuiper et al. 1996, Kuiper 
et al. 1997). They share about 96% structural homology in their DBD and 53% homology in 
their LBD (Kuiper et al. 1996), which suggests that the receptors bind similar DNA elements 
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but may have a distinct spectrum of ligands. Indeed, the receptors differ in their affinities for 
several natural and synthetic compounds (Barkhem et al. 1998, Kuiper et al. 1998). The ERβ 
protein is smaller than that of ERα and the receptors differ markedly in their N-terminal AF-1 
domain and the C-terminal AF-2 domain (Fig. 4). This suggests that the transcriptional 
activation of different estrogen-responsive genes may be different due to promoter and cell-
specific factors and by different interactions of the N- and C-terminal domains with proteins in 
the transcription complexes; for example, ERα and ERβ have opposite functions at the AP-1 
site (Paech et al. 1997). The human ERβ gene shows approximately 89% identity to that of rat, 
88% to mouse, and 47% to human ERα (Enmark et al. 1997). 
Several splicing variants for both ERs have been identified (Fuqua et al. 1993, Friend et al. 
1995, Zhang et al. 1996, Chu and Fuller 1997, Leygue et al. 1998, Moore et al. 1998, Petersen 
et al. 1998, Hanstein et al. 1999, Hodges et al. 1999, Li et al. 2003). The biological and 
physiological roles of most ERα splice variants have not been clarified. Some ERβ splice 
variants, such as ERβ-503 and ERβcx, do not bind E2 and they have also been reported to 
have a dominant negative effect on ERα and ERβ-mediated activation of target genes 
(Maruyama et al. 1998, Ogawa et al. 1998). ERβcx has been of particular interest due to its 
expression in human cancers (Ogawa et al. 1998).  
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Figure 4. Comparison between rat ERα and ERβ protein. The bars represent rat ER molecules divided into their 
structural domains. Amino acid positions are indicated at region boundaries. The percentage of amino acid 
identity in the A/B (AF-1, N-terminal), C (DNA binding), D (hinge), E (ligand binding), and F (AF-2, C-
terminal) domains is demonstrated. Similar homologies are present in the respective domains of human and 
mouse ER subtypes. Modified from Kuiper and Gustafsson FEBS Lett. 1997;410:87-90, with permission of 
Elsevier Inc., New York, NY. 
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3.5. Estrogen receptor expression  
Estrogen receptors have been demonstrated in numerous rat, mouse, and human tissues both at 
the mRNA (Kuiper et al. 1996, Mosselman et al. 1996, Couse et al. 1997, Enmark et al. 1997, 
Kuiper et al. 1997, Tremblay et al. 1997) and at the protein (Saunders et al. 1997, Taylor and 
Al-Azzawi 2000) level. The receptors have clearly different tissue distribution, and when co-
expressed in the same tissue, they usually have a distinct cell-specific localization. ERα is 
predominantly expressed in the uterus, placenta, testis, kidney, and liver. ERβ, on the other 
hand, predominates in many non-classical target tissues including the ovary, prostate 
epithelium, bladder, lung, the gastrointestinal (GI) tract, spleen, thymus, lymph nodes, and 
bone marrow. Both receptors are found in the kidney, mammary gland, different regions of 
brain, bone, adrenal gland, the cardiovascular system, and epididymis. There may, however, 
be some species-specific variance in the expression pattern (Kuiper et al. 1996, Enmark et al. 
1997).  
The co-expression of ERα and ERβ in some tissues suggests that the receptors may interact 
with each other. It has been demonstrated that, in addition to binding DNA as homodimers, the 
ERs also form heterodimers, which may increase their functional capability to regulate gene 
expression (Cowley et al. 1997, Pettersson et al. 1997). For example, although the uterus 
predominantly expresses ERα, it is not free of ERβ, and it appears that ERβ modulates the 
uterotrophic responses of ERα in the uterus (Weihua et al. 2000, Lecce et al. 2001). 
In the vasculature, estrogen receptors have been detected in the arteries and veins of several 
species (Malinow et al. 1963, McGill and Sheridan 1981, Horwitz and Horwitz 1982, Lin and 
Shain 1985, Perrot-Applanat et al. 1988, Orimo et al. 1993). They are present in vascular 
endothelial (Colburn and Buonassisi 1978, Kim-Schulze et al. 1996, Venkov et al. 1996) and 
smooth muscle cells (Nakao et al. 1981, Karas et al. 1994, Losordo et al. 1994, Bayard et al. 
1995, Register and Adams 1998, Hodges et al. 2000, Taylor and Al-Azzawi 2000) as well as 
in cardiac myocytes (Grohe et al. 1997, Saunders et al. 1997, Grohe et al. 1998) and 
fibroblasts (Grohe et al. 1997). Vascular cells also express variant forms of the ERs (Karas et 
al. 1995, Inoue et al. 1996, Chu and Fuller 1997, Hodges et al. 1999, Li et al. 2003).  
In addition to the classical nuclear receptors, plasma membrane estradiol binding sites have 
been identified in vascular and other tissues (Razandi et al. 1999), and these mediate rapid 
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intracellular signalling cascades (Chambliss et al. 2000, Russell et al. 2000, Chambliss et al. 
2002, Li et al. 2003). Finally, changes in plasma estrogen concentration regulate the levels of 
ERs in the tissues. ER levels in the cytosol of human artery were highest in the late follicular 
phase of the menstrual cycle (Lantta et al. 1983, Leiberman et al. 1990). Moreover, estrogen 
treatment caused a redistribution of the ER from the cytoplasmic to nuclear compartment in 
the rabbit aorta (Lin and Shain 1985). 
3.6. The role of gender and estrogens in different vasculoproliferative disorders 
Coronary heart disease is a major cause of morbidity and mortality in both men and women. 
The incidence of CHD and the related cardiovascular complications is rare in premenopausal 
women (Barrett-Connor and Bush 1991, Isles et al. 1992). However, the risk increases 
markedly after the menopause (Kannel et al. 1976, Colditz et al. 1987, van der Schouw et al. 
1996, Jacobsen et al. 1997, Joakimsen et al. 2000), and compared to men, there is a 5- to 10-
year delay in the onset of the disease in women (Wenger 1997, Maxwell 1998) (Fig. 5).  
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Figure 5. A. Annual rate of coronary heart disease in men (solid line) and women (dashed line) from the 
Framinghman Heart Study. Modified from Castelli WP. Am. J. Obstet. Gynecol. 1988;158(6 Pt 2):1553-60, with 
permission of Elsevier Inc., New York, NY. B. Leading causes of death of women in Finland in 1999. Finnish 
Heart Association, Helsinki, Finland, with permission. CVD, cardiovascular disease; CA, cancer; DEM, 
dementia; ALZ, Alzheimer’s disease; RESP, respiratory disease. 
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These observations are most likely due to the protective effect of endogenous female sex 
hormones, and particularly of estrogens. This hypothesis has been supported by population 
studies, which suggest that in primary prevention, women using postmenopausal hormone 
replacement therapy (HRT) have approximately a 35% to 50% lower rate of CHD (Stampfer 
et al. 1985, Stampfer et al. 1991, Grady et al. 1992, Grodstein et al. 1996, Grodstein et al. 
2000). However, in the secondary prevention of cardiovascular disease, HRT does not seem to 
offer any overall benefit (Hulley et al. 1998, Herrington et al. 2000).  
Male gender has been associated with increased risk for post-angioplasty restenosis (Holmes 
et al. 1984). On the other hand, the short-term results of PTCA in women have been 
considered less satisfactory with lower initial success rate and higher mortality rate than in 
men. Many of the differences may be explained by worse baseline characteristics in women, 
such as older age, unstable angina, congestive heart failure, diabetes, hypertension, and 
hypercholesterolemia, as well as smaller vessel diameter, and more coronary tortuosity. The 
long-term results after PTCA are comparable or better in women, with similar symptomatic 
improvement, lower rates of restenosis, and improved survival compared to men (Cowley et 
al. 1985, Bell et al. 1993, Kelsey et al. 1993, Arnold et al. 1994, Weintraub et al. 1994, Bell et 
al. 1995, Ruygrok et al. 1996). Also with coronary stents, long-term survival is better or equal 
in women than in men (Alfonso et al. 2000, Antoniucci et al. 2001, Mehilli et al. 2003). There 
are few data on the effects of HRT on the outcome after PTCA and the results are inconsistent 
(O'Keefe et al. 1997, Abu-Halawa et al. 1998, Khan et al. 2000, Khan et al. 2003). Recently, 
estrogen-releasing stents have been introduced, and preliminary results are promising (New et 
al. 2002, Joung et al. 2003, Abizaid et al. 2004) 
Gender also influences the outcome in experimental and clinical transplantation. In general, 
male recipients of a female transplant are at increased risk for rejection, allograft 
vasculopathy, and graft loss (Keogh et al. 1991, Mehra et al. 1994, Marino et al. 1995, Brooks 
et al. 1996, Vereerstraeten et al. 1999, Zeier et al. 2002) (Fig. 6). Allografts from male donor 
have a better 1-year survival rate, since acute rejection episodes are more common in females 
(Cecka 1986, Esmore et al. 1991, Fabbri et al. 1992, Neugarten and Silbiger 1994, Brooks et 
al. 1996, Meier-Kriesche et al. 2001). However, evidence exists that long-term allograft 
outcome is improved in female recipients (Neugarten and Silbiger 1994, Meier-Kriesche et al. 
2001).  
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Figure 6. Donor gender-related differences in the survival of first cadaveric kidney transplants performed 
between 1985 and 2000. Kidney transplants from female donors had a significantly lower survival rate, 
particularly in male recipients. Zeier et al. J Am Soc Nephrol 2002;13:2570-2576, with permission of the 
authors and Lippincott Williams & Wilkins, Baltimore, MD. 
Reasons for the gender-related differences are largely unknown. Some studies suggest that 
nephron underdosing, i.e. a smaller kidney size in females versus males, may play a role 
(Brenner et al. 1992, Mackenzie et al. 1995). Antigenicity and immunological factors are 
probably also important. HLA mismatching reduces the survival of female donor grafts more 
than that of male grafts (Cecka 1986). Broadly sensitized recipients have a lower 1-year 
survival rate when they receive a female kidney (Zhou and Cecka 1989). Females, especially 
those who have been pregnant, are also more frequently sensitized than males (Suciu-Foca et 
al. 1983, Koka and Cecka 1989, Regan et al. 1991, van Kampen et al. 2001). However, 
gender-related differences in graft survival are seen even in HLA-identical siblings, possibly 
pointing to an additional role of non-HLA factors (Zeier et al. 2002). An alternative view is 
that, sex hormones, not the sex of the donor, are responsible for the recipient gender-related 
differences. In ovariectomized female rats, progression of chronic allograft nephropathy is 
more rapid in allografts of female donor than of male donor (Muller et al. 1999). However, 
estrogen supplementation prevents the functional decline of female donor grafts whereas 
testosterone increases rejection in kidneys of male origin (Muller et al. 1999). Moreover, 
testosterone impairs long-term allograft outcome in male animals, while estrogen improves 
allograft survival in female animals, irrespective of the donor gender (Antus et al. 2002). 
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The role of estrogen in vasculoprotection has been intensely studied in experimental models. 
Endogenous estrogens protect female rats against neointimal thickening and gonadectomy 
abolishes the effect (Chen et al. 1996). Estrogen treatment inhibits fatty streak and lesion 
formation in ApoE deficient mice (Bourassa et al. 1996, Elhage et al. 1997). Moreover, it 
inhibits neointima formation after carotid balloon injury in rabbits (Foegh et al. 1994), rats 
(Chen et al. 1996), and mice (Sullivan et al. 1995); immunologically-induced vascular 
fibroproliferative dysplasia in rabbit aorta (Cheng et al. 1991) and cardiac allografts (Foegh et 
al. 1987); as well as diet-induced coronary artery atherosclerosis in monkeys (Adams et al. 
1987, Adams et al. 1990). 
3.7. Mechanisms behind estrogen’s vasculoprotective effect 
Despite years of intense study, the mechanisms behind estrogen’s vasculoprotective effects are 
still incompletely understood. Estrogens have beneficial effects on serum lipid concentrations 
(Stevenson et al. 1993, The Writing Group for the PEPI Trial 1995); however, evidence exists 
that estrogen-induced alterations in the lipids can account for only approximately one third of 
the observed vasculoprotective effects (Bush et al. 1987, Grady et al. 1992, Mendelsohn and 
Karas 1999). Thus, the direct estrogenic effects on the vascular wall most probably make up a 
major part of its vasculoprotective properties. Estrogen is believed to exert its effects both 
directly via a rapid non-genomic pathway, such as the rapid vasodilatory effect (Farhat et al. 
1996a) (Table 2), and via a genomic pathway through nuclear ERs, which regulate the 
transcription of target genes (Table 3). The non-genomic effects occur within minutes while 
the genomic effects take place over hours. 
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Table 2. Potential non-genomic mechanisms behind estrogen’s vasculoprotective actions 
Physiologic or 
pathophysiologic    
effect of E2  
Potential mechanism References 
 
  
Vasodilation 
   
Changes in membrane ionic 
permeability, particularly Ca2+ and K+ 
ion channel functions 
Upregulation of cAMP and cGMP 
Increased production and release of 
NO from ECs, possibly through 
activation of eNOS by ERα located in 
the plasma membrane 
Farhat et al. 1996a, Mendelsohn and Karas 
1999, Dubey and Jackson 2001  
                                                                
Farhat et al. 1996a, Dubey and Jackson 2001 
Mendelsohn and Karas 1999,                
Dubey and Jackson 2001 
  
   
 
The development of ERα, ERβ, and ER(α,β) double knock out-mice has increased our 
understanding of the ER-mediated effects in the vasculature. Vascular SMCs isolated from 
ERβ-deficient mice have abnormalities in ion channel function, and they develop sustained 
systolic and diastolic hypertension with age (Zhu et al. 2002). Estrogen’s vasculoprotective 
effects on the vascular injury response were preserved in mice lacking either ERα or ERβ, but 
not in mice lacking both ERs (Iafrati et al. 1997, Karas et al. 1999, Karas et al. 2001), which 
suggested that they are mediated by the ERs, and that either of the known ERs is sufficient to 
protect against vascular injury. However, the mice developed no neointima, and the analysis 
was based only on changes in the medial layer. This differs markedly from the case in other 
animals and man, which makes it difficult to evaluate the relative roles of the two receptors in 
vasculoprotection. 
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Table 3. Potential genomic mechanisms behind estrogen’s vasculoprotective actions 
Physiologic or 
pathophysiologic 
effect of E2  
Potential mechanism References 
   
Vasodilation Upregulation of prostacyclin synthase    
and eNOS 
Downregulation of renin, ACE, ET-1,   
and AT 1 receptor  
Farhat et al. 1996b,                        
Mendelsohn and Karas 1999,                
Dubey and Jackson 2001 
   
Cell adhesion  Downregulation of VCAM, ICAM,         
E-, and P-selectin  
Caulin-Glaser et al. 1998, Cushman et al. 
1999, Mendelsohn and Karas 1999,      
Zanger et al. 2000, Dubey and Jackson 2001, 
Oger et al. 2001 
   
Endothelial recovery 
(reendothelialization) 
Upregulation of bone marrow-derived 
endothelial progenitor cell production 
Stimulation of EC replication, possibly  
via upregulation of VEGF and bFGF 
Inhibition of EC apoptosis 
Farhat et al. 1996b, Mendelsohn and Karas 
1999, Dubey and Jackson 2001,            
Iwakura et al. 2003, Strehlow et al. 2003b 
   
SMC function 
   
Inhibition of MAP kinase activity and the 
subsequent SMC proliferation and 
migration  
Downregulation of IGF-1, IGF-1R, c-fos, 
c-myc, and cell cycle proteins  
Suzuki et al. 1996, Dubey and Jackson 2001, 
Takahashi et al. 2003 
   
Extracellular matrix 
synthesis 
Downregulation of collagen and elastin 
synthesis 
Upregulation of matrix metalloproteinases  
Farhat et al. 1996b,                            
Mendelsohn and Karas 1999,               
Zanger et al. 2000, Dubey and Jackson 2001 
   
Lipid metabolism        
           LDL↓, HDL↑  
triglycerides↑
Upregulation of apolipoproteins A and E, 
LDL receptor, and lipoprotein lipase  
Downregulation of apolipoprotein B and 
lipoprotein(a) 
Mendelsohn and Karas 1999,                  
Dubey and Jackson 2001 
   
Inflammation Downregulation of IL-1, IL-6, MCP-1, 
MHC II, and TNF-α 
Saito et al. 1997, Mendelsohn and Karas 
1999, Srivastava et al. 1999,                  
Dubey and Jackson 2001, Koh et al. 2001 
   
Coagulation, 
thrombosis,          
and fibrinolysis 
Downregulation of fibrinogen, 
antithrombin III, protein S, PAI-1  
Upregulation of TPA  
Mendelsohn and Karas 1999,                
Dubey and Jackson 2001 
   
Antioxidant effect Downregulation of free radical production, 
inhibition of LDL oxidation 
Upregulation of superoxide dismutase 
Dubey and Jackson 2001, Laufs et al. 2003, 
Strehlow et al. 2003a 
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3.8. Estrogen receptors as targets for vasculoprotective drug therapies 
Although the vasculoprotective properties of E2 have been widely demonstrated both in 
epidemiological and experimental studies, its effects have been difficult to understand and 
exploit due to harmful side-effects in the reproductive system: while being antiproliferative in 
the vasculature, estrogen-treatment increases the risk for endometrial and breast cancer (Key 
and Pike 1988, Barrett-Connor 1992, Colditz et al. 1995).   
However, the discovery of ERβ and the distinct tissue distribution and transcriptional 
regulation of the two ERs prompted us to generate a hypothesis that perhaps estrogen’s 
different effects in different tissues could be separated with receptor subtype-selective, i.e. 
tissue-selective compounds - and the hypothesis was subsequently proven to be correct 
(Makela et al. 1999). An ideal compound should have estrogenic effects in the cardiovascular 
system and bone, while being neutral in breast and uterus. 
3.9. Selective estrogen receptor modulators (SERM) 
SERMs are compounds that act as ER agonists in some tissues while being antagonists in 
others (MacGregor and Jordan 1998, Morello et al. 2002). SERMs act on their target cells by 
diffusing into the cell and binding to the two ERs with variable affinities. According to current 
knowledge, the action of a SERM in a given tissue is dependable on several factors, such as 
the ER subtype-selectivity of the compound, the predominant ER expressed in the tissue, and 
the nature of the target gene promoter (Webb et al. 1995, Paech et al. 1997, Jones et al. 1999). 
The conformational change that takes place upon binding of the SERM to either of the ERs, 
and particularly, the position of helix 12 in the LBD, depends on the SERM involved, and it 
plays a critical role in the agonist or antagonist configuration of the ER that determines the 
ability of the ER-ligand complex to interact with coregulatory proteins and exert either the 
estrogen agonist or antagonist response in the tissue (Martin et al. 1988, McDonnell et al. 
1995, Brzozowski et al. 1997, Shiau et al. 1998, Paige et al. 1999, Pike et al. 1999). Also, the 
expression of coregulatory proteins has been shown to vary in different cells and tissues 
(Voegel et al. 1996, Kalkhoven et al. 1998, Kurebayashi et al. 2000) 
The SERMs currently in clinical use, namely tamoxifen, raloxifene, and toremifene, are used 
for the prevention and treatment of breast cancer and postmenopausal osteoporosis (Fig. 7). In 
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addition, several promising compounds have been described, including idoxifene and 
ospemifene (Pace et al. 1997, Nuttall et al. 1998, DeGregorio et al. 2000, Qu et al. 2000, Taras 
et al. 2001) (Fig. 7). In general, SERMs have minimal effects on uterine endometrium. 
Tamoxifen, however, is associated with a 2-6 fold increased risk for endometrial cancer, 
which has limited its use outside chemotheraphy (Bernstein et al. 1999, Bergman et al. 2000). 
The data presently available on the role of SERMs in vasculoprotection are promising. 
Tamoxifen and raloxifene have been reported to have beneficial effects on lipids (Walsh et al. 
1998, Wenger and Grady 1999, De Leo et al. 2001), to reduce markers of cardiovascular risk 
(Love et al. 1994, Walsh et al. 1998), and to be associated with lower rates of cardiovascular 
events in humans (McDonald et al. 1995, Barrett-Connor et al. 2002). Both are also favourable 
in lipid-induced experimental atherosclerosis (Bjarnason et al. 1997, Reckless et al. 1997, 
Williams et al. 1997), although contradictory results also exist (Clarkson et al. 1998, Castelo-
Branco et al. 2004). Although ospemifene has a cholesterol-lowering effect in the rat (Qu et al. 
2000), it showed a neutral effect on vascular markers in a recent clinical study (Ylikorkala et 
al. 2003). Only some data are available on the effects of SERMs on restenosis: raloxifene and 
idoxifene inhibited neointima formation in the rat (Kauffman et al. 2000, Yue et al. 2000).  
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Figure 7. Molecular structures of tamoxifen (left), raloxifene (middle), and ospemifene (right). 
3.10. Phytoestrogens 
Phytoestrogens are a large family of plant-derived molecules possessing various degrees of 
estrogenic activity. They are present in many food products, such as soy and rye, as well as in 
many food supplements. Phytoestrogens are traditionally divided into three main groups, 
namely isoflavones, lignans, and cumestans, of which isoflavones comprise the most common 
group (Albertazzi and Purdie 2002). The two major isoflavones are genistein and daizein, and 
37  
their major natural sources are soy and red clover (Eldridge and Kwolek 1983). 
Epidemiological studies suggest that phytoestrogen-rich diet is associated with reduced 
incidence of breast and prostate cancer, cardiovascular disease, osteoporosis, and climacteric 
symptoms (Setchell et al. 1984, Adlercreutz et al. 1991, Somekawa et al. 2001). 
Phytoestrogens’ cardiovascular benefits have been shown in several studies, where they have 
improved plasma lipid levels (Anderson et al. 1995, Anthony et al. 1996, Baum et al. 1998), 
vascular reactivity, and arterial compliance (Honore et al. 1997, Nestel et al. 1997, Figtree et 
al. 2000), and had antioxidant effects (Tikkanen et al. 1998, Deodato et al. 1999, Jenkins et al. 
2000), as well as reduced experimental atherosclerosis (Yamakoshi et al. 2000, Alexandersen 
et al. 2001, Clarkson et al. 2001).   
Phytoestrogens bind to the ERs, and as with SERMs, the conformational change of the 
receptor, and especially the position of helix 12 of the LBD, differs depending on the type of 
ligand that binds to the receptor (Pike et al. 1999). Thus, these compounds could also be called 
‘phytoSERMs’. Genistein (Fig. 8) has approximately 20 times higher binding affinity for ERβ 
than ERα (Kuiper et al. 1997). In micromolar concentrations, genistein also inhibits several 
enzymes, such as tyrosine kinase, which may contribute to its effects, particularly its 
antiproliferative actions, in high doses (Akiyama et al. 1987). 
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Figure 8. Molecular structure of genistein. 
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AIMS OF THE STUDY 
This study was based on the observation that there are two estrogen receptors that differ in 
their tissue distribution and regulation of gene transcription, which might explain why 
estrogen can, at the same time, induce proliferation in the reproductive system while being 
antiproliferative in the cardiovascular system. Data on the expression and regulation of the two 
ERs in different vasculopathies, and the identification of potential mechanisms behind 
estrogen’s vasculoprotective action, could enable the development of tissue-selective 
estrogens for the prevention of restenosis and allograft arteriosclerosis.  
The specific aims were: 
1. To investigate the expression and regulation of ERα and ERβ in response to vascular injury 
using rat carotid denudation and cardiac transplantation models. 
2. To try to differentiate between estrogen’s beneficial vasculoprotective properties and its 
harmful side-effects with selective targeting of ERβ. 
3. To compare and correlate the vasculoprotective properties of four different SERMs with 
natural estrogen in vitro and in vivo, concentrating particularly on SMC biology. 
4. To investigate the interactions between natural estrogen and peptide growth factors in 
estrogen's 
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METHODS 
1. Rat models for restenosis and allograft arteriosclerosis 
Experimental animals. Female or male Wistar rats and specific pathogen-free inbred male 
DA (AG-B4, RT1a) and WF (AG-B2, RT1u) rats, purchased from the Laboratory Animal 
Center, University of Helsinki, Helsinki, Finland (I, II, IV) or from Harlan, Holland (III) were 
used for denudation and transplantation studies, respectively. All animals received humane 
care in compliance with the Guide for the Care and Use of Laboratory Animals published by 
the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The 
investigation was approved by the Haartman Institute Ethical Committee for Animal Studies, 
and the permission to perform the experiments was granted by the Government of the County 
of Southern Finland. The rats that received estrogenic drugs were placed on a soy-free diet 
(Special Diet Services, Essex, UK) seven days before operation (I, III, IV); in experiment II, 
the rats received the basic diet (Altromin, Standard Diet, Chr. Petersen A/S, Ringsted, 
Denmark). Tap water was given ad libitum. The rats were anesthesized with chloralhydrate, 
240 mg/kg i.p., and 0.25 mg/kg s.c. buprenorphine (Temgesic, Reckitt & Colman, Hull, UK) 
was used for peri- and post-operative pain relief. 
Rat carotid and aortic denudation. Female rats were ovariectomized through abdominal 
incision seven days before denudation to restrain physiological estradiol production. The left 
common carotid artery (I) or the thoracic aorta (III, IV) was denuded of endothelium by an 
intraluminal passage of a 2 French (2F) Fogarty arterial embolectomy catheter (Baxter 
Healthcare Corporation, Santa Ana, CA), which was introduced through the external carotid 
artery or the left iliac artery, respectively. The balloon was inflated with 0.2 ml of air and 
passed three times in the carotid artery or five times in the thoracic aorta. Thereafter, the 
external carotid artery, or iliac artery, was ligated and the wound was closed. At sacrifice, the 
artery was removed, a middle section was processed for histology, and the rest was snap-
frozen in liquid nitrogen and stored at -70°C until used. In female rats, the uterus was also 
removed, weighed, and processed for histology. 
Rat cardiac transplantation. Intra-abdominal heterotopic rat cardiac allografts were 
transplanted using a microsurgical technigue modified from Ono and Lindsey (Ono and 
Lindsey 1969). Syngeneic transplantations were performed from DA to DA rats and 
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allogeneic transplants from DA to WF rats. Ice-cold heparin-PBS was perfused through the 
vena cava inferior of the donor, and thereafter, caval vessels and pulmonary veins were 
ligated, and aorta and pulmonary artery were cut 3-5 mm above their origin. Donor heart was 
preserved in ice-cold PBS for 15 min. Then, donor heart aorta and pulmonary vein were 
anastomosed to recipient abdominal aorta and inferior vena cava between renal vessels and 
aorta bifurcation using 9-0 nylon suture. Total ischemic time was 45±15 min, during which the 
donor heart was cooled with cold PBS gauze. The grafts started beating vigorously after 
circulation into the graft was established. The function of the graft was evaluated by 
abdominal palpation and all the grafts were beating at removal.  
2. Drug regimens 
Cyclosporine A (CsA) was used for base immunosuppression of allogeneic transplants. Fifty 
mg/ml of CsA infusion substance (Sandimmun; Sandoz Pharma AG, Basel, Switzerland) was 
dissolved in 200 mg/ml Intralipid (KabiVitrum, Stockholm, Sweden) to a final concentration 
of 1.0 mg/ml. Cyclosporine was administered daily s.c., 2 mg/kg/d for the first seven days and 
then 1 mg/kg/d. Whole blood CsA 24-hour trough levels were measured weekly with 
radioimmunoassay (Sandimmun-Kit; Novartis, Basel, Switzerland). 
17β-estradiol (E2; Sigma, St Louis, MO) was dissolved in dimethyl sulphoxide (DMSO; 
Sigma) and 0.9% NaCl (Baxter, Vantaa, Finland), and administered s.c. using the following 
doses: 0.0025, 0.025, 0.25, and 2.5 mg/kg/d, in one injection per day. For long-term follow-up, 
a dose of 2.5 mg/kg/d was chosen, based on the dose responses. The treatment was initiated at 
the time of operation. Thereafter, the animals were weighed daily, and the dose was adjusted 
according to weight changes. Control animals received an equal volume of vehicle (DMSO, 
0.9% NaCl, 1:1). Serum 17β-estradiol levels were measured with competitive 
radioimmunoassay (RIA) at the Laboratory of the Department of Obstetrics and Gynecology, 
Helsinki University Central Hospital, Helsinki, Finland. For in vitro studies, a 50 mM stock 
solution was prepared in DMSO and this stock solution was diluted in cell culture medium and 
used for the experiments at concentrations of 0.0006-50 ?M. The concentration of DMSO in 
all in vitro experiments remained below 0.1%. 
Genistein was generously provided by Dr. William Helferich (Michigan State University, 
East Lansing, MI) or purchased from Plantech (York, UK). It was dissolved in DMSO and 
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0.9% NaCl, and administered s.c. using the same doses as with E2. Genistein was also used 
for in vitro experiments and the solutions were prepared similar to E2. 
SERMs. Tamoxifen (Sigma), raloxifene (Evista; Eli Lilly, Houten, The Netherlands), 
ospemifene (Hormos Medical Corporation, Turku, Finland), and fispemifene (Hormos 
Medical) were all dissolved in DMSO and 0.9% NaCl. The drugs were administered s.c. as a 
single daily injection with the following doses: 0.0025, 0.025, 0.25, 2.5, and 25 mg/kg/d. For 
long-term follow-up a dose of 2.5 mg/kg/d was used. The treatment was initiated at the time of 
operation. The animals were weighed daily, and the dose was adjusted according to changes in 
weight. Control animals received an equal volume of vehicle (DMSO, 0.9% NaCl, 1:1). 
Solutions for in vitro experiments were prepared as with E2.  
ICI 182,780 (Faslodex; kindly provided by Tuula Ikonen, Zeneca Pharmaceuticals, Helsinki, 
Finland), a pure anti-estrogen, was dissolved in DMSO and 0.9% NaCl and administered s.c. 
as a single daily injection with the following doses: 0.0025, 0.025, 0.25, and 2.5 mg/kg/d. For 
long-term follow-up a dose of 2.5 mg/kg/d was used. Solutions for in vitro experiments were 
prepared as described above. The relative binding affinities (RBA) of all the compounds used 
in the study are given in Table 4. 
Table 4. Relative binding affinities (RBA) of the different compounds to ERα and ERβ  
Drug RBA References 
 ERα ERβ  
    
17β-estradiol 100 100 Kuiper et al. 1998 
Genistein 4 87 Kuiper et al. 1998 
Raloxifene 69 16 Kuiper et al. 1998 
Tamoxifen 4 3 Kuiper et al. 1998 
Fispemifene 1.1 0.55 Lauri Kangas, personal communication 
Ospemifene 0.82 0.59 Qu et al. 2000 
ICI 182,780 89 166 Wakeling et al. 1991, Kuiper et al. 1997 
    
 
3. Quantitative RT-PCR 
Total RNA isolation. Total RNA was isolated from snap-frozen E2- or vehicle-treated aorta 
specimens by the guanidium isothiocyanate method (Chomczynski and Sacchi 1987). After 
isolation and purification, RNA concentrations were measured by a spectrophotometer and the 
quality of RNA was confirmed by electrophoresis through 1% agarose gel. 
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Quantitative RT-PCR. Total RNA was isolated as described above. Six serial dilutions were 
made with an appropriate amount of total RNA from each group, mixed with either 106 or 107 
molecules of synthetic template RNA containing a 46-nucleotide insert and reverse transcribed 
to cDNA in a mixture containing 1x RT buffer (Promega, Madison, WI), 300 mM dNTP 
(GeneAmp; Perkin Elmer, Foster City, CA), 10 pmol of antisense primer (IGF-1, 
TCTGTAGGTCTTGTTTCCTGCA; IGF-1R, GACGGACTACTACCGGAAAGG; PDGF-A, 
ATGTCACACGCCACGTACAT; PDGF-Rα, CACACTGAAGGTTCCGTTGAAG; PDGF-
B, CACTACTGTCTCACACTTGCAGG; PDGF-Rβ, TCATAGGGTACATGTAGGGGG 
AT), 20 U RNasin (RNasin Ribonuclease Inhibitor; Promega), and 100 U of reverse 
transcriptase (M-MLV-RTase Reverese Transcriptase, RNase H Minus; Promega) at +37°C 
for 90 minutes. Two ml of cDNA mixture was supplemented with 10x PCR buffer (GeneAmp, 
Perkin Elmer), radioactive tracer, 10 pmol of antisense primer, 10 pmol of sense primer (IGF-
1, GGAAAATCAGCAGTCTTCCAAC; IGF-1R, TTCCGATGATCTCCAGGAAG; PDGF-
A, GACAAACCTGAGAGCCCATG; PDGF-Rα, GAGAAGATTGTGCCGCTGAGT; 
PDGF-B, CTGAGCTGGACTTGAACATGAC; PDGF-Rβ, TCGTCCTCAACATTT 
CGAGC), and 2.5 U of Taq polymerase. The samples were heated to +95°C for 5 minutes and 
cycled 40 times (+94°C for 30 seconds, +60°C for 30 seconds, and +72°C for 1 minute). The 
samples were electrophoresed through 2% agarose gel and incorporated radioactivity was 
quantitated. Accession numbers are given in the original publication (IV). 
4. In situ hybridization 
Probe Preparation. The complementary RNA probes were synthesized according to the 
Manufacturer’s (Promega) directions in the presence of 35S-UTP (Amersham Pharmacia) by 
using the following cDNA fragments as templates. A 400-bp fragment (from the 5’ 
untranslated region, starting nucleotide sequence GAATTC, ending nucleotide sequence 
CTACGT) of rat ERβ cDNA and a 200-bp fragment (from the 3’ untranslated region, F-
domain region, starting nucleotide sequence ATGGGA, ending nucleotide sequence 
TAGCAG) of the rat ERα cDNA were subcloned to pBluescript II KS (+) (Stratagene, La 
Jolla, CA) vector and used for the production of corresponding antisense and sense cRNA 
probes. RNA probes transcribed from opposite strands of the same plasmid template were 
adjusted to the same specific radioactivity.  
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In situ hybridisation. Rat carotid arteries and heart grafts were removed at different time 
points post operation, fixed in 3% paraformaldehyde solution for 4 hours, transferred to saline, 
and processed for paraffin embedding. Human heart allograft endomyocardial biopsies came 
from the pathology files of the Transplantation Laboratory, and the permit to use the biopsies 
in this study was granted by the Helsinki University Central Hospital Ethical Committee. 
Uterus and bladder specimens were chosen for control tissues, as uterus is known to express 
predominantly ERα and bladder ERβ (Kuiper et al. 1997).  
Serial sections of the different specimens were made under RNase free conditions. To ensure 
that the different specimens were comparable, sections from each group and the control tissues 
were placed on the same silanized microscopy slide and hybridized in identical conditions, 
either for ERα or ERβ. After deparaffinization and rehydration, the sections were denatured in 
0.2 M HCl, heat-denatured in 2x standard saline citrate (SSC) at +70°C, and treated with 
proteinase K (1 ?g/ml). The sections were then post-fixed with 4% paraformaldehyde, 
acetylated with 0.25% acetic anhydride in 0.1 M triethanolamine, and dehydrated and air-
dried. The slides were hybridised with antisense and sense RNA probes at +60°C overnight, 
washed in 4x SSC, treated with RNase A (20 ?g/ml), and washed sequentially in SSC 
solutions with 1 mM DTT. Finally, the slides were rinsed in 0.1x SSC with 1 mM DTT, 
dehydrated in graded ethanols, and air-dried. Then, the slides were dipped into 
autoradiography emulsion (NBT-3; Eastman Kodak, Rochester, NY), exposed for 7-14 days, 
and developed, counterstained, dehydrated, and mounted with Permount. The number of 
grains was calculated from three randomly-selected areas per slide using 100x objective and 
oil immersion technique. 
5. Western blotting 
Snap-frozen aortas were crushed and homogenized with Ultra-Turrax (Janke & Kunkel, 
Staufen, Germany) in 1 ml of buffer (50 mmol/L Tris-HCl pH 7.5, 150 mmol/L NaCl, 1 
mmol/L EDTA, 50 mmol/L NaF). The homogenate was supplemented with 1% Triton X-100, 
2 mmol/L PMSF, 100 units of aprotinin, and 10 mmol/L benzamidine, and after incubation at 
+4°C for 1 hour, the lysate was clarified by centrifugation. The supernatant was split and 
incubated with 10 µl of appropriate rabbit polyclonal antibodies for IGF-1, IGF-1R, PDGF-
AA, PDGF-Rα, PDGF-BB, and PDGF-Rβ, and further with 50 µl of Protein A sepharose 
suspension in lysis buffer (+4°C, 1 hr). Captured immunocomplexes were washed and 
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separated using standard SDS-PAGE (15% polyacrylamide for receptors and 5% for ligands). 
The gel was transferred to a nitrocellulose membrane and blocked with 20 mmol/L NaH2PO4, 
80 mmol/L Na2HPO4, 100 mmol/L NaCl, 0.1% Tween-20, and 5% skimmed milk powder 
(+4°C, overnight). Then, the membrane was incubated with corresponding antibodies (Santa 
Cruz Biotechnology) in blocking buffer (RT, 1 hr). After washing in blocking buffer (without 
5% skimmed milk powder; RT, 30 min), the membrane was incubated with secondary 
antibodies (RT, 1 hr), washed again and treated with ECL (Amersham International Plc., Little 
Chalfont, England). The signal was visualized by exposure to Kodak X-OMAT-AR film. 
Signal intensity was measured with Macintosh NIH image software (National Technical 
Information Service, Springfield, VI). Details for the antibodies are given in the original 
publication (IV). 
6. Histological and immunohistological evaluation 
Morphometry. For evaluation of vascular morphological changes, carotid and aortic 
specimens were fixed in 3% paraformaldehyde (pH 7.4) solution for 4 hours, transferred to 
saline, and processed for paraffin embedding. Two ?m thick cross sections were made and 
stained with Mayer’s hematoxylin and eosin. The absolute number of cells in the intimal, 
medial, and adventitial layers was calculated from paraffin cross sections using 400x 
magnification. Intimal (inside lamina elastica interna) and medial areas (between lamina 
elastica interna and lamina elastica externa) and vessel lumen were quantitated with 
Macintosh NIH image software and the intimal/medial area ratio was calculated from these 
values. For uterus histology, the specimens were processed as above, and specimens from 
vehicle-treated rats were compared blind to specimens from rats that were treated with the 
different drugs for 7 or 28 days. 
Quantitation of cell proliferation in vivo. Proliferating cells were labeled with intravenous 
injection of 300 ?l of 5-bromo-2'-deoxyuridine (BrdU; Pharmacy of Helsinki University 
Central Hospital, Helsinki, Finland), 3 hours before sacrifice. Incorporation of the labeling 
reagent was visualized by immunohistochemical staining of paraffin cross sections, using a 
commercial immunoperoxidase method (Vectastain Elite ABC kit; Vector Laboratories, 
Burlingame, CA) as described below. Finally, the absolute number of positively-stained nuclei 
was counted microscopically using 400x magnification. 
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Immunohistochemistry. Serial frozen sections or cultured rat SMC were air-dried on silane 
coated slides, fixed in acetone at -20°C for 20 min, and stored at -20°C until used. Before 
immunostaining, the slides were refixed with chloroform and air-dried. Sections from 
paraformaldehyde-fixed paraffin-embedded specimens were deparaffinized before staining. In 
case of polyclonal primary antibodies, the sections were sequentially incubated with 1.5% 
normal goat serum (Vector Laboratories), primary antibody (+4°C, overnight), biotinylated 
goat anti-rabbit antibody, avidin-peroxidase complex (Vectastain Elite ABC Kit; Vector 
Laboratories), 0.1% hydrogen peroxide, and 3-amino-9-ethylcarbazole (AEC; Sigma), with 
intervening washes with Tris-buffered saline. Finally, the slides were counterstained with 
hematoxylin and coverslips were mounted. With monoclonal primary antibodies, the slides 
were incubated with 1.5% normal horse serum (Vector Laboratories) and a mouse monoclonal 
primary antibody (+4°C, overnight). The subsequent steps were performed as above, except 
that biotinylated horse anti-mouse secondary antibody was used. With IGF-1 and IGF-1R 
antibodies, the sections were first incubated with 5% normal horse serum (Vector 
Laboratories) and thereafter with a primary antibody (+4°C, overnight), secondary antibody, 
avidin-alkaline phosphatase complex (Vectastain ABC-AP Kit; Vector Laboratories), and 
alkaline phosphatase substrate (Vector Red Alkaline Phosphatase Substrate Kit I; Vector 
Laboratories). The antibodies used are presented in Table 5.  
To establish the specificity of the ER antibodies to rat and human ER subtypes, their reactivity 
to rat and human uterus and bladder were investigated. Additional controls for polyclonal 
primary antibody staining were performed using 10- to 20-fold molar excess of neutralizing 
synthetic peptides to the corresponding antibodies, and by omitting the primary antibody.  
Monoclonal primary antibody stainings were controlled by replacing the primary antibody 
with irrelevant antibody (clone DAK-GO1; DAKO). None of the control stainings showed any 
immunoreactivity. 
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Table 5. Antibodies used for immunohistochemistry 
Species Specificity Clone/code Antigen Source Dilution 
      
BrdU M 0744 Bromodeoxyuridine conjugated 
to bovine serum albumin 
DAKO, Glostrup, 
Denmark 
1:20 
ERα M 7047 Recombinant human ER protein     DAKO 1:50 
Mouse,
mono-
clonal 
 NCL-ER-6F11 Recombinant full-length human 
ERα protein 
Novocastra, Newcastle 
upon Tyne, UK 
1:40 
Rabbit, 
poly-
clonal 
ERβ PAI-310 A synthetic peptide corresponding 
to the C-terminal amino acid 
residues 467-486 of rat ERβ 
Affinity Bioreagents, 
Golden, CO 
1:200 
  PAI-311 A synthetic peptide corresponding 
to the N-terminal amino acid 
residues 55-70 of rat/mouse ERβ 
Affinity Bioreagents 1:600 
 IGF-1 AFP4892898 Human IGF-1 protein National Institute of 
Digestive and Kidney 
Diseases, Bethesda, MD 
1:2000 
 IGF-1R sc-712 A synthetic peptide corresponding 
to the N-terminal amino acid 
residues 31-50 of human IGF-1R 
Santa Cruz 
Biotechnology,       
Santa Cruz, CA 
1:200 
 PDGF-AA ZP-214 Purified recombinant human 
PDGF-AA protein 
Genzyme,      
Cambridge, MA 
1:100 
 PDGF-Rα sc-338 A synthetic peptide corresponding 
to the C-terminal amino acid 
residues of human PDGF-Rα 
Santa Cruz 
Biotechnology 
1:100 
 PDGF-BB ZP-215 Purified recombinant human 
PDGF-BB protein 
Genzyme 1:100 
 PDGF-Rβ sc-339 A synthetic peptide corresponding 
to the C-terminal amino acid 
residues of human PDGF-Rβ 
Santa Cruz 
Biotechnology 
1:100 
 Factor VIII A0082 Von Willebrand Factor isolated 
from human plasma 
DAKO 1:200 
      
 
ERα and ERβ stainings were evaluated semiquantitatively by two different methods; 
separately from the intimal, medial, and adventitial layers of the vessels, or from the arteries, 
veins, myocardium, and inflammatory cells of the cardiac allografts. The intensity of staining 
was graded as follows: 0/- = no visible staining; + = weak staining; ++ = moderate staining; 
+++ = intense staining. The frequency of positive cells was expressed as the fraction of 
positively stained cells out of total: 0 = 0-10%; 1 = 15-35%; 2 = 40-60%; 3 ? 65%. Growth 
factor immunostaining was graded separately from intimal, medial, and adventitial layers of 
the aorta as follows: - = no visible staining; (+) = few cells with very faint staining; + = some 
cells with weak staining; ++ = moderate staining with multifocal expression; +++ = intense 
staining throughout the vessel compartment. With BrdU and factor VIII, the results were 
expressed as positive cells per cross section. All gradings were made blinded of the type of 
specimens. 
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7. Cell culture studies 
Rat primary smooth muscle cell cultures. Primary vascular SMC were isolated from 9 to 
11-day old DA (AG-B4, RT1a) rat aortas using a method modified from Thyberg et al. 
(Thyberg et al. 1983). The aortas were opened longitudinally and the endothelial layer was 
scraped off. Then, the adventitia and media were separated, and the medial layer was digested 
with 0.1% collagenase and DNAse in PBS at +37ºC for 30 minutes. The cells were 
centrifuged, suspended in culture medium, and thereafter, allowed to attach to plastic flasks. 
Primary cells were used at passages 10-15 for the experiments. For identification, the cells 
were grown until 70% confluency on glass slides, serum-starved for 24 hours and then 
stimulated with 10% FCS or left unstimulated for another 24 hours. All cells expressed SMC 
α-actin, and furthermore, 80% of the serum-starved and FCS-stimulated SMC expressed ERβ 
while only 1% of the serum-starved and none of the FCS-stimulated SMC expressed ERα.  
The cells were subcultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, Paisley, 
Scotland) supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 100 IU/ml 
penicillin, and 100 µg/ml streptomycin. The medium for experiments with estrogenic 
compounds consisted of DMEM without phenol red (BioWhittaker, Cambrex Bioproducts, 
Verviers, Belgium) and 5% Dextran charcoal-treated Fetal Bovine Serum (DCC-FBS; 
HyClone, Logan, UT), to exclude the estrogenic effects of phenol red in the medium or 
endogenous estrogens in the serum. In vitro studies were done in triplicate and repeated three 
times. 
3H-TdR-incorporation. The cells were seeded on 96-well plates (5,000 cells/well) in DMEM 
supplemented with 5% FCS. The next day the growth medium was changed to serum-free and 
phenol red-free medium containing 0.5% bovine serum albumin (BSA). Following 48-hour 
serum starvation, proliferation was induced with either with PDGF-B (20 ng/ml, Upstate 
Biotechnology, Lake Placid, NY) or 5% DCC-FBS, and simultaneously, the serially-diluted 
drugs and 3H-TdR (Amersham Pharmacia, Amersham, UK) were added to the wells, and 
incubation was continued for 24 or 48 hours. The amount of incorporated, radioactively 
labeled thymidine to the DNA, which corresponds to the amount of DNA synthesis in each 
well, was measured using 10% trichloroacetic (TCA) precipitation and counted separately 
from each well using a liquid scintillation counter (RackBeta; Wallac, Turku, Finland). 
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Smooth muscle cell migration. SMC migration was quantitated using Transwell culture 
chambers (Costar, Cambridge, MA) where the upper and lower culture chambers are separated 
by a polycarbonate filter with 8-?m pores. The chambers were first coated with collagen (20 
?g/ml; Rat Tail Collagen, Type 1; Upstate Biotechnology, Lake Placid, NY) at +4ºC for 24 
hours. Primary rat aortic SMC (50,000 cells/chamber) were seeded in the upper chamber in 
phenol red-free DMEM containing 0.5 % BSA, and PDGF (60 ng/ml) was added to the lower 
chamber, and the cells were allowed to adhere to the filter for 60 minutes. The serially-diluted 
drugs were added to the upper chamber, and after 24-hour incubation at +37ºC, the filters were 
removed, fixed with methanol, and stained with hematoxylin. The cells that had migrated on 
the lower side of the filter were quantitated by counting specific cross-sectional fields with a 
light microscope using 400x magnification.  
8. Tissue culture studies 
Aortic explant culture. Aortic explants were prepared from ovariectomized female Wistar 
rats that were denuded of endothelium on day –2. The rats were treated with the compounds at 
the dose of 2.5 mg/kg/d s.c. prior to sacrifice.  Experiment media consisted of phenol red-free 
DMEM supplemented with 10 % DCC-FBS. At sacrifice, a small proximal part of each aorta 
was prepared for histology and vessel morphology was determined as described above. The 
rest of the aortas, including all layers of the vessel, were opened longitudinally and explants 
measuring 1x1 mm were prepared using a McIlwain tissue chopper (Mickle Laboratory 
Engineering, Surrey, England). The explants were placed individually into the wells of a flat-
bottomed 96-well plate (Nunc, Roskilde, Denmark) with 20 µl basal medium to keep the 
explants damp. Thereafter, they were allowed to adhere to the tissue culture plates in a +37˚C 
incubator for 2 hours. Two hundred µl of experiment medium with serially-diluted drugs was 
then added to each well. 
Quantitation of explant outgrowth. Each well was observed after 24 and 48 hours of culture 
and counted as positive for "sprouting" if one or more cells had grown out of the explants. The 
distance that the leading edge of migrating cells in each well had travelled from the explant 
was measured using a calibrated graticule (Olympus, Tokyo, Japan). To quantitate 
proliferating cells, the explants were pulsed with 3H-TdR on day 0. On day 2 the outgrowing 
cells were detached from the wells with trypsin and the explants were digested with pepsin 
(Merck, Darmstadt, Germany) at +37˚C for 50 minutes. Then, the content of each well was 
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harvested with a Dynatech Harvester (Dynatech Labs, Sussex, UK) and mixed with OptiScint 
Hisafe (LKB-Wallac, Turku, Finland). Radioactivity was measured with a Rackbeta liquid 
scintillation counter. 
9. Statistical analysis 
All data are given as mean ± SEM. Significance of the observed differences between different 
groups was tested either with one-way ANOVA followed by Fisher’s PLSD test, or in the case 
of unequal variances or only two groups, with Student’s unpaired t test. Prior to these tests, 
normal distribution of the data was tested. In addition, linear regression analysis, preceded by 
logarithmic transformation, was used for dose-response analyses. All analyses were performed 
using Statview 4.1 software (Abacus Concepts, Berkeley, CA). Values of p<0.05 were 
regarded as statistically significant. 
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RESULTS 
1. Estrogenic effects in the rat carotid and aorta denudation injury models (I, III-IV) 
Mechanical injury was inflicted to rat carotid artery or aorta with a balloon catheter, which 
resulted in complete loss of the luminal endothelium.  The first cells appeared in the intima 
after day 3. Proliferation peaked in the media at 3 days and in the intima at 7 days, and this 
was followed by a rapid increase in the number of intimal nuclei and intimal area within 7 to 
14 days post-operation. Thereafter, intimal growth subsided and further increase was small. 
The number of medial nuclei remained unaltered throughout the time interval investigated.  
Although estrogen’s vasculoprotective properties on the injury response have been previously 
demonstrated in the rodents (Foegh et al. 1994, Sullivan et al. 1995, Chen et al. 1996), no 
comprehensive dose-response studies exist, which is why those were performed first. Effective 
therapeutic doses for long-term follow-up were chosen based on the dose-responses. On day 7, 
estradiol treatment dose-dependently reduced the number of intimal nuclei in both the carotid 
artery (r=0.864) and aorta (r=0.693). With the highest dose (2.5 mg/kg/d, s.c.) the intimal 
nuclei number remained at the level of normal artery.  
Figure 9. Effects of 17β-estradiol (E2) treatment (2.5 
mg/kg/d) on the ovariectomized female rat aorta at 0, 7, 
14, and 28 days after denudation injury are presented in 
the upper figure. Mean number of nuclei in the vessel 
intima in the vehicle (closed circle) and E2 (open circle) 
groups, and mean number of proliferating (BrdU-
positive) nuclei in the vehicle (closed triangle) and E2 
(open triangle) groups are shown, n=6-10. The grey 
rectangle represents the number of nuclei (endothelial 
cells) in a normal female rat aorta. 
Representative microphotographs of vehicle (left) and 
E2-treated (right) female rat aorta at 28 days after 
denudation injury are presented in the lower figure. The 
arrows indicate lamina elastica internae. Lumen facing 
up, x400.      
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Long-term treatment up to 28 days (2.5 mg/kg/d) resulted in approximately 30%-50% 
reduction in the number of intimal nuclei (Fig. 9) and intimal area of the aorta, and 50%-70% 
reduction in the number of proliferating (BrdU-incorporating) nuclei (Fig. 9). Concomitantly, 
a 4-fold increase in reendothelialization was observed. Serum estradiol levels with the highest 
dose (2.5 mg/kg/d) were approximately 10 times higher than the levels in a normal woman and 
100 times higher than in a normal female rat. 
Treatment of male rats with 0.25 mg/kg/d of E2, s.c., resulted in significant inhibition in the 
number of intimal nuclei, intimal area, and proliferating nuclei on day 7, and the changes were 
comparable to those observed in female rats. 
2. Estrogen receptor expression in the rat vascular wall after endothelial injury (I) 
The expression and localization of ERα and ERβ mRNA in male rat carotid artery at different 
time points after endothelial denudation injury were investigated by in situ hybridisation (Fig. 
10). Both ERα and ERβ transcripts were expressed at low levels in the normal carotid artery. 
ERβ was upregulated markedly in the media, and especially in the neointima, within 3 to 28 
days post-injury, peaking on day 7, while expression of ERα remained unchanged.  
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Figure 10. Expression of ERα (open circle) and ERβ (closed circle) mRNA in male rat carotid artery at different 
time points after denudation injury determined by in situ hybridisation. Data are given as mean±SEM, n=3 and 
three countings per section.   
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In situ hybridisation and immunohistochemistry demonstrated that ERβ mRNA and protein 
were colocalized with the SMCs in the media and neointima, over 90% of which were positive 
for α-actin. 
3. Estrogen receptor expression in rat and human cardiac allografts (II) 
The localization and intensity of the expression of ERα and ERβ mRNA and protein were 
investigated by in situ hybridisation and immunohistochemistry in rat male-to-male cardiac 
allografts and human male-to-male heart allograft endomyocardial biopsies with various 
degrees of acute or chronic rejection.  
 
Almost no ER mRNA was seen in the normal (non-transplanted) DA rat heart arteries, veins, 
heart muscle, or inflammatory cells; however, ERβ protein was present. ERβ mRNA and 
protein were prominently expressed in the rat allogeneic (under rejection) and syngeneic graft 
(subject to reperfusion injury) vessels and stroma, whereas ERα mRNA and protein were 
present in small amounts only. The vessels, stroma, and inflammatory cells in human 
endomyocardial biopsies stained positively for ERβ protein, whereas some ERα was seen only 
in the myocardium and inflammatory cells. When correlated to the expression levels of ERs in 
uterus and bladder, the former of which expresses mainly ERα and the latter ERβ (Kuiper et 
al. 1997), it was observed that the expression of ERβ in the grafts was close to its expression 
levels in bladder epithelium, whereas the expression of ERα was – even at its highest - only 
30%-50% of the levels in uterine endometrium. Interestingly, the expression of ERβ in the 
grafts showed only a weak correlation with the intensity of rejection. 
4. Differentiation between estrogen’s vasculoprotective and uterotrophic effects (Ι) 
To investigate if estrogen’s vasculoprotective properties could be differentiated from its 
gender-related effects, we compared the effects of 17β-estradiol (which binds both ERs with 
high affinity) and the phytoestrogen genistein (which binds ERβ 20 times stronger than ERα) 
on neointimal thickening and uterine growth following carotid artery denudation injury in 
ovariectomized female Wistar rats. To exclude the effect of food-derived (phyto)estrogens, the 
rats were placed on soy-free diet at the time of ovariectomy.  
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Both E2 (r2=0.746) and genistein (r2=0.946, p=0.5 as compared to E2) had a dose-dependent 
inhibitory effect on the number of intimal nuclei within the dose range from 0.0025 to 2.5 
mg/kg/d. Moreover, both compounds similarly reduced the number of replicating (BrdU-
incorporating) nuclei in the neointima. In vitro, in the supraphysiological dose range, both 
compounds equally inhibited the PDGF-induced 3H-TdR-incorporation (DNA synthesis) and 
migration of cultured rat vascular SMC.  
However, only E2 (r2=0.954) dose-dependently increased the weight of the uterus and induced 
typical estrogen-related morphological changes, such as hyperplastic endometrium, stromal 
thickening, and mild stromal inflammation, while genistein had no effect (r2=0.096, p=0.0003 
as compared to E2).  
5. SERMs’ vasculoprotective properties in the injured rat vascular wall (III) 
All SERMs studied, as well as the pure anti-estrogen ICI 182,780, dose-dependently (from 
0.0025 to 25 mg/kg/d s.c.) inhibited the number of intimal nuclei at 7 days after aorta 
denudation injury in ovariectomized female rats. Tamoxifen, raloxifene, and ICI 182,780 also 
reduced SMC proliferation (the number of BrdU-incorporating nuclei) in the intimal layer, 
similarly to E2. When treated with the most effective dose (2.5. mg/kg/d) for 28 days, only 
tamoxifen and ospemifene reduced the number of intimal nuclei and intimal area, and the 
effect was comparable to E2. Tamoxifen (p=0.0002), raloxifene (p=0.03), ospemifene 
(p=0.04), and fispemifene (p=0.0006) (2 to 3-fold), but not ICI 182,780, significantly 
enhanced reendothelialization at 28 days post-injury. 
In order to study the reversibility of the vasculoprotective effect, additional groups of rats 
were treated with the compounds for 14 days, whereafter the compounds were replaced with 
vehicle for another 14 days. No rebound effect was observed with E2, tamoxifen, or 
ospemifene, and furthermore, a smaller neointima size than with continuous treatment was 
achieved with raloxifene, fispemifene, and ICI 182,780. Interestingly, with RA the number of 
factor VIII-expressing (endothelial) cells in the luminal side of the artery doubled after 
discontinuation of the treatment. 
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Finally, only E2 dose-dependently increased the weight of the uterus and induced typical 
estrogen-related morphological changes, while only weak (tamoxifen, ospemifene, 
fispemifene) or no (raloxifene, ICI 182,780) such effect was observed with the SERMs. 
6. Estrogenic effects in the rat vascular SMC and aortic explant cultures (I, III) 
Estradiol inhibited DNA synthesis (3H-TdR incorporation) of cultured rat primary SMC. The 
inhibitory effect was weak or neutral in the physiological dose range and became significant 
only at micromolar concentrations. Estradiol also had a dose-dependent inhibitory effect on 
the PDGF-induced migration of SMC at concentrations above 10-8 M. All SERMs had 
estrogenic effects on SMC DNA synthesis and, overall, their antimitogenic effects were 
superior to estrogen. All compounds, excluding fispemifene, inhibited SMC migration as well. 
In the aortic explants, estradiol reduced 3H-TdR incorporation and migration of SMC already 
at nanomolar concentrations. All SERMs were anti-mitogenic, and all but fispemifene were 
also anti-migratory. Interestingly, the pure antiestrogen ICI had opposite effects in the SMC 
and explant cultures: it was antimitogenic to SMC but had neutral effects on the explant 
cultures. 
7. Regulation of growth factor expression in the rat vascular wall by estrogen (IV) 
Growth factor mRNA and protein expression and localization in the denuded male rat aorta 
were investigated at 15 min, 3, and 7 days post-injury. Quantitative RT-PCR and Western 
blotting showed significant upregulation of IGF-1, PDGF-Rα, and PDGF-B mRNA and 
protein after injury, concomitantly with the increase in proliferative SMC in the developing 
neointima. Administration of estradiol completely abolished IGF-1 mRNA and protein 
expression whereas it had no effect on IGF-1R. It also downregulated PDGF-Rα, and PDGF-
B, but had no effect on PDGF-Rβ. Estrogen therapy reduced immunoreactivity for IGF-1, 
PDGF-A, PDGF- Rα, and PDGF-B, while no changes were seen with respect to IGF-1 or 
PDGF- Rβ. 
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DISCUSSION 
Estrogen is a pleiotropic steroid hormone with varied effects on cell proliferation, 
differentiation, and growth in different parts of the body. Previously, it was difficult to 
understand how estrogen may have growth-promoting effects in some tissues, such as the 
uterus and breast, and growth-inhibitory effect in other tissues, including the cardiovascular 
system. The paradigm, however, was potentially unravelled by the discovery of a second ER, 
ERβ, in 1996, and currently, many of the contrasting effects of estrogen may be explained by 
the tissue- and/or cell type-specific expression and regulation of ERα and ERβ. The 
mechanisms behind estrogen’s vasculoprotective properties are still incompletely understood.  
1. Experimental models for studying restenosis and allograft arteriosclerosis 
Preclinical experimental studies on the development of restenosis or allograft arteriosclerosis 
and their intervention in man can only be carried out in an in vitro environment with human 
cell lines or tissues. Therefore, experimental models in animals are needed for the in vivo 
studies. Nonhuman primates, such as baboon, have the closest resemblance to human, but they 
are expensive, difficult to handle and maintain in the laboratory, and not readily available. 
Rat carotid artery and aorta denudation injury models have been widely used to study the 
development of restenosis and the coexistent SMC proliferation and migration in the vascular 
wall (Clowes et al. 1983a, Clowes et al. 1983b, Reidy et al. 1983, Myllarniemi et al. 1997). 
The models differ from the human setting in some respects. Rat artery has a much thinner 
endothelium and no natural intima (Sims 1989), and the injury in the rat is induced in a 
healthy artery whereas the human vessel is already diseased. Also, the rat model does not take 
into account several risk factors, such as hypertension or genetic susceptibility. Moreover, 
human but not rat angioplasty requires antiplatelet/anticoagulant therapy. Compared to 
baboon, the injury response is stronger and reendothelialization slower in rat carotid artery 
(Du Toit et al. 2001). However, the rat model enables us to study the events in the vascular 
wall in an in vivo environment, which makes it superior to all in vitro experiments. With 
respect to this study, the beneficial vascular properties of estrogen have been shown both in 
rodents and in humans (Stampfer et al. 1985, Grady et al. 1992, Foegh et al. 1994, Chen et al. 
1996). Moreover, human ERβ gene shows approximately 89% identity to rat ERβ (Enmark et 
al. 1997).  
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It has recently become apparent that most of the cells contributing to neointimal hyperplasia in 
restenosis as well as in allograft arteriosclerosis derive possibly from recipient-derived 
multipotent somatic stem cells and not from the vascular media (Hillebrands et al. 2000, 
Saiura et al. 2001, Shimizu et al. 2001, Hu et al. 2002, Sata et al. 2002, Tanaka et al. 2003). 
Therefore, the use of cultured medial SMC or SMC lines alone may not give a correct picture 
of the events in the injured vascular wall. Previous experiments have shown that intimal injury 
in vivo activates aortic explant outgrowth (sprouting) in vitro (Grunwald and Haudenschild 
1984, Aavik et al. 2002), and that remarkable upregulation of sprouting occurs within 2-14 
days post-denudation. Our unpublished data show that the majority (>75%) of the outgrowing 
cells express SMC α-actin, and numerous cells show features of undifferentiated endothelial- 
and myofibroblast-like cells. Due to the complexity of the vascular tissue, the aortic explant 
model shows more variability than the cell culture models, and thus, demonstration of 
statistical significance may be more difficult. However, the comparability of the specimens 
was ensured by morphological analysis of histological specimens extracted from each vessel. 
Although further identification of the outgrowing cells needs to be done, we may conclude 
that the aortic explant model allows us to evaluate the in vivo injury-induced changes in the 
vessel wall in an ex vivo setting, and it enables us to separately quantitate the proliferative and 
migratory responses without excluding the influx of precursor cells. This study (III) further 
demonstrates that the aortic explant model more reliably resembles the situation in the in vivo 
vessel: E2 inhibited clearly, and at lower concentrations, explant outgrowth, migration and 
proliferation in the explant model compared to cultured SMC. Also, ICI had contrasting 
effects in the explants vs. SMC: it was inhibitory on SMC proliferation in vitro, but not in the 
aortic explants ex vivo, which is similar to the in vivo setting.   
2. Contribution of the two estrogen receptors on estrogen’s vasculoprotective properties 
Estrogen’s effects in the body are mediated via both a rapid nongenomic pathway and a 
genomic pathway that requires the transcriptional regulation of target genes. Most of its 
vasculoprotective properties, excluding vasomotor effects, are thought to occur via the 
genomic pathway. Both ERs have been detected in cultured vascular SMC of cynomolgus 
monkeys (Register and Adams 1998) and in rat and human arteries (Lindner et al. 1998, 
Hodges et al. 2000). However, the relative contribution of the two ERs in mediating estrogen’s 
actions in the vasculature remains unclear. 
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Knock-out mice, where either or both of the ERs have been deleted, have brought some 
insight in this issue. The finding that estrogen’s vasculoprotective properties were preserved in 
ERα-/- mice (Iafrati et al. 1997) suggested that estrogens vascular effects are mediated via 
ERβ rather than ERα. This encouraged us to further study the role of ERβ in the injured 
vascular wall. ERβ clearly predominated over ERα in the rat carotid artery after denudation 
injury, colocalizing with the SMC in the media, and particularly in the neointima (I). ERβ was 
also predominantly expressed in rat and human cardiac allograft arteries, veins, myocardium, 
and inflammatory cells, whereas ERα remained at low level only (II). Furthermore, estrogen’s 
vasculoprotective effect could be differentiated from its uterotrophic effect with specific 
targeting to ERβ (I). Predominant expression of ERβ in the normal and injured vascular tissue 
has, thereafter, been supported by studies in baboon and man (Hodges et al. 2000, Aavik et al. 
2001). Contrary to these findings, ERα was shown to be upregulated in rabbit cardiac-aortic 
allografts (Lou et al. 1998a). However, ERα mRNA was increased only 3-fold, which is 
remarkably less than the nearly 40-fold increase in ERβ mRNA in the injured rat artery (I). 
Moreover, the expression of ERβ was not determined in that study. Finally, estrogen’s 
vasculoprotective properties were preserved in ERβ knock-out mice (Karas et al. 1999), but 
not in double knock-out mice (Karas et al. 2001), which suggests that, unless additional ERs 
exist, either of the two ERs is sufficient to protect against vascular injury. However, the mice 
in these studies did not develop any neointima and the analysis was based on modest changes 
seen in the media only, which differs markedly from the case in other rodents, primates, or 
humans. Furthermore, in one study, there was practically no injury-response at all (Pare et al. 
2002). Thus, we cannot draw a conclusion on the relative roles of the two ERs in 
vasculoprotection based solely on the knock-out mouse data. 
An alternative, or complementary, way to approach the contribution of the two ERs in 
estrogen’s vasculoprotection would be ER subtype-selective ligands. Until recently, genistein 
was the most ERβ-selective compound available with approximately 20-fold affinity 
difference for ERβ vs. ERα (Kuiper et al. 1998). Treatment of ovariectomized rats with 
genistein, inhibited neointima formation and the proliferation and migration of vascular SMC 
equally to E2, while only E2 had a dose-dependent uterotrophic effect (I). Thus for the first 
time, estrogen’s vasculoprotective effect was differentiated from its uterotrophic effect with 
special targeting to ERβ. Genistein can also exert antimitogenic effects through inhibition of 
tyrosine kinases (Akiyama et al. 1987, Epstein et al. 1997, Nelson et al. 1997, Schonherr et al. 
58  
1997, Takahashi et al. 1997). However, this was not the case in this study since genistein’s 
tyrosine kinase inhibition has been reported to require relatively high (>10 ?M) concentrations 
of genistein, whereas nanomolar concentrations are sufficient to exert significant ER-mediated 
effects (Makela et al. 1994, Kuiper et al. 1998). In our study, the inhibitory effects on vascular 
SMC proliferation in vitro occurred already at concentrations of 1 ?M and on SMC migration 
at 0.1 ?M. Furthermore, the in vivo doses were estimated to result in nanomolar serum 
concentrations (Santell et al. 1997).  
Despite the relatively good ER-subtype selectivity of genistein, it still has ERα agonist 
activity (Kuiper et al. 1998). Only recently, highly ER subtype-selective compounds with no 
cross-reactivity have been described (Meyers et al. 2001, Harris et al. 2002, Sun et al. 2002, 
Harrington et al. 2003, Harris et al. 2003). Current understanding, gained from the knock-out 
mouse and ER subtype-selective estrogen studies, is that ERα is crucial to the uterotrophic, 
anorectic, lipid-lowering, and bone-sparing actions of estrogen (Harris et al. 2002), whereas 
ERβ seems to have immunomodulatory or anti-inflammatory, but not uterotrophic or 
mammotrophic activity (Harris et al. 2003). However, as the knock-out data on the vascular 
injury response may not be reliable and no data, besides with genistein (I), have yet been 
published on ER subtype-selective ligands, the concept in the vasculature remains unclear. 
Interestingly, recent in vitro studies suggest that estrogen’s inhibitory effect on SMC 
proliferation and the concomitant mitogen-activated protein kinase inhibition is mediated via 
ERβ (Geraldes et al. 2003, Watanabe et al. 2003). This clearly supports our hypothesis.  
It could also be questioned, if the estrogenic compounds’ effects on neointima formation and 
SMC kinetics are mediated via ERs or via some alternative pathways. Both promoting and 
contradictory data exist.  Bakir and coworkers have demonstrated that estrogen’s 
vasoprotective effect in the injured rat carotid is blocked with a pure anti-estrogen ICI 182,780 
(Bakir et al. 2000), which suggests that the effects are receptor mediated. ICI also blocked the 
inhibitory effect of E2 on human vascular SMC (Dubey et al. 2000) and, furthermore, vascular 
injury response was totally abolished in the ER double knock out mice (Karas et al. 2001). On 
the other hand, ICI, which is defined as a pure antiestrogen with no agonist activity, may also 
have anti-mitogenic activity on vascular SMC in vitro and in vivo (III; Bakir et al. 2000). ICI 
has been shown to decrease DNA synthesis in neonatal rat cardiac myocytes via an ER-
independent pathway by regulating cell cycle proteins and extracellular signal-regulated 
kinase (Mercier et al. 2003). Furthermore, in an ER-negative ovarian cancer cell line, ICI 
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dose-dependently inhibited cell proliferation and induced apoptosis (Ercoli et al. 1998). 
Potential ER-independent mediators of estrogen action in the vasculature might include 
estrogen-related receptors (ERR) (Sladek et al. 1997, Susens et al. 2000, Sumi and Ignarro 
2003) and plasma membrane estrogen binding sites (Chambliss et al. 2000, Russell et al. 2000, 
Chambliss et al. 2002, Li et al. 2003). Also, estradiol metabolites, such as 2-hydroxyestradiol 
and 2-methoxyestradiol, which have minimal affinity for the ERs, have been demonstrated to 
inhibit SMC and cardiac fibroblast growth via an ER-independent pathway in vitro, and even 
more potently than estradiol alone (Nishigaki et al. 1995, Dubey et al. 1998, Dubey et al. 
1999). Thus, ER-independent mechanisms may also play some role in, and add to, the 
vasculoprotective effects of estrogen and related compounds.  
3. Estrogen’s interactions with growth factor signalling 
Peptide growth factors are important in the development of vascular neointimal hyperplasia as 
they are upregulated in the vessel wall and induce the proliferation and migration of vascular 
SMC (Majesky et al. 1990, Cercek et al. 1991, Miano et al. 1993), and as blocking of their 
action inhibits neointimal thickening (Ferns et al. 1991b, Hayry et al. 1995, Myllarniemi et al. 
1997).  
The interplay of estrogen with different growth factors is complex and varies in different 
tissues. First, estrogen-induced proliferation in the uterus is accompanied by increased 
expression of polypeptide growth factors or their receptors, such as IGF-1, EGF, and TGF-β 
(Murphy et al. 1987, Huet-Hudson et al. 1990, Nelson et al. 1992, Das et al. 1994). Second, 
these same growth factors can activate estrogen receptors in a ligand-independent manner 
(Ignar-Trowbridge et al. 1992, Aronica and Katzenellenbogen 1993). Mitogen-activated 
protein kinase (MAPK), activated by growth factors such as IGF-1, PDGF, and EGF through 
their cell surface receptors, is capable of phosphorylating the AF-1 domain of ERα and ERβ, 
which results in potentiation of transactivation of the ER (Kato et al. 1995, Bunone et al. 1996, 
Tremblay et al. 1999). In contrast, estrogen has been shown to downregulate MAPK activation 
in vascular SMC (Morey et al. 1997). Furthermore, in rabbit cardiac allografts and aortic 
SMC, estradiol-treatment inhibits IGF-1 mRNA and protein expression (Lou et al. 1997, Lou 
et al. 1998b). Estrogens also downregulate PDGF-A mRNA in monocytes and vascular SMC 
in vitro (Shanker et al. 1995, Kikuchi et al. 2000). 
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There has been incomplete information on at which level estrogen intervenes in the growth 
factor – MAPK cascade. In this study, estradiol-treatment downregulated the injury-induced 
expression of IGF-1, PDGF-Rα, and PDGF-B mRNA and protein in the male rat aorta, and 
with immunohistochemistry, an inhibitory effect on PDGF-A protein expression was observed 
as well (IV). Decreased amounts of growth factors, or their receptors, are likely to result in 
decreased activation of downstream proteins, such as MAPK, c-myc, and c-fos (Morey et al. 
1997), and decreased proliferation and migration of SMC in the vessel wall.  
The most prominent changes were seen in the expression of IGF-1, which is a rather weak 
mitogen alone (Ferns et al. 1991a). However, IGF-1 is an important progression factor for 
PDGF-stimulated proliferation (Banskota et al. 1989, DeAngelis et al. 1995), and furthermore, 
changes in IGF-1/IGF-1R interactions modulate the effects of VEGF in the vasculature (Smith 
et al. 1999, Hellstrom et al. 2001). The understanding of these interactions adds special 
significance to the regulation of IGF-1 expression by estrogen.  
PDGF-A has been thought to exert mainly mitogenic effects (Majesky et al. 1990, Rekhter and 
Gordon 1994). Increased expression of PDGF-A, and -Rα have also been reported in rat 
cardiac allograft arteriosclerosis and obliterative bronchiolitis (Kallio et al. 1999, Sihvola et al. 
1999), and shown to correlate with increased allograft arteriosclerosis (Sihvola et al. 1999). 
This suggests that the inhibition of the PDGF/PDGF–Rα axis by estrogen may inhibit the 
mitogenic responces in the developing neointima, and furthermore, the development of, not 
only restenosis, but also of allograft arteriosclerosis.  
The variability in the PDGF-A and PDGF-B expression in Western blotting and 
immunohistochemistry was likely due to the growth factors’ predominant localization in 
vascular neointima. Neointima comprised of only a minor part of the vessel, whereas most of 
the protein for Western blotting originated from the media and adventitia. Changes in media 
and adventitia, as quantitated by immunohistochemistry, were small or non-existent, and this 
was probably reflected in Western blotting as rather small changes in growth factor protein 
expression. 
Finally, it seems logical that the predominant receptor in the cell/tissue determines the 
estrogenic response to growth factors. In the uterus, where ERα predominates, estrogen-
treament results in cell proliferation, as a concequence of increased production of growth 
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factors, which in turn may strengthen the ERα-mediated transactivation. Also in vascular ECs, 
estrogen induces proliferation through ERα, which results in increased reendothelialization 
after vascular injury (Krasinski et al. 1997, Somjen et al. 1998, Brouchet et al. 2001). In 
contrast, in the vascular SMC, where ERβ is the dominant subtype (I, II), estrogen-treatment is 
accompanied by decreased growth factor production (IV), resulting in downregulation of cell 
proliferation and cell migration. Indeed, it could be speculated that ERα and ERβ have a kind 
of “ying-yang” relationship in the body, with ERα inducing cell growth and ERβ repressing it. 
In addition, ERβ may act as a dominant negative regulator of ERα-mediated signalling 
(Pettersson et al. 2000, Lindberg et al. 2003). In the uterus, ERβ has been reported to modulate 
the uterotrophic responses induced by ERα, by reducing IGF-1 synthesis and the resulting cell 
proliferation (Weihua et al. 2000).  
4. Is there a role for estrogen in regulating the influx of precursor cells? 
Although both replication and migration contribute to neointimal thickening, it has been 
suggested that migration may be more important in the process (Clowes and Schwartz 1985, 
Du Toit et al. 2001). Furthermore, as mentioned, most of the cells contributing to the 
thickened neointima seem to originate either from circulating or bone marrow-derived 
vascular precursors, or both (Hillebrands et al. 2000, Saiura et al. 2001, Shimizu et al. 2001, 
Hu et al. 2002, Sata et al. 2002, Tanaka et al. 2003). Their route to the vessel wall is not clear, 
although some studies suggest that adventitia has an important role in neointima formation 
since adventitial activation precedes neointima formation (Shi et al. 1996a, Shi et al. 1996b, 
Frosen et al. 2001). Also, growth factors, such as PDGF and VEGF, have been proposed to be 
important regulators of the differentiation of vascular precursor cells, either to SMCs or ECs, 
respectively (Yamashita et al. 2000). Estrogen has been shown to attenuate adventitial 
fibroblast migration in vitro (Li et al. 1999) as well as adventitial activation after rat carotid 
balloon injury in vivo (Oparil et al. 1999). Furthermore, estrogen significantly enhanced 
endothelial progenitor cell production, mobilization, and incorporation in the recovering artery 
in response to vascular injury. As estrogen significantly inhibited the outgrowth, proliferation, 
and migration of cells from aortic explants (III), and better than the proliferation of cultured 
vascular SMC, it would be interesting to hypothesize that estrogen inhibits the proliferation of 
neointimal (precursor) cells at extravascular sites, such as bone marrow, which results in 
reduced influx of precursor cells into the vascular wall. This needs further investigation.    
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5. Current controversies on postmenopausal hormone replacement therapy  
In recent years, the pros and cons of hormone replacement therapy have come under intense 
scrutiny. Large randomised prospective trials, such as the Heart and Estrogen/Progestin 
Replacement Study (HERS) and Women’s Health Initiative (WHI), reported that treatment of 
postmenopausal women with oral conjugated equine estrogen (CEE) plus 
medroxyprogesterone acetate (MPA) did not have any overall benefits on cardiovascular 
disease, and furthermore, might increase the risk for breast cancer (Hulley et al. 1998, 
Rossouw et al. 2002). The women participating in the HERS had pre-existing coronary heart 
disease, and although the WHI was described as a primary prevention trial, a remarkable 
portion of the participants had risk factors for CHD (smoking, obesity, diabetes, 
hypercholesterolemia), and/or received antihypertensive medication, statins, or aspirin, and 
some even had a history of cardiovascular events and/or interventions. Also, only one third of 
the women started the therapy close to their menopause – the average patient age was 63 
years. Thus, current data indicate that estrogens are not beneficial in the secondary prevention 
of CHD, whereas the data on their efficacy in primary prevention is strong (Stampfer et al. 
1985, Stampfer et al. 1991, Grady et al. 1992, Grodstein et al. 1996, Grodstein et al. 2000). 
Observational studies, such as the Nurses’ Health study, on the other hand, have been 
critisized on the grounds that their results might reflect the “healthy woman effect”, i.e. 
women who take estrogens tend to be more educated, have more favourable lifestyles, fewer 
risk factors, and are more compliant with treatment than women, who do not take the 
estrogens. However, it is obvious that randomized double-blind primary prevention studies in 
perimenopausal women (with menopausal symptoms) are extremely difficult, if not 
impossible, because the relieve of menopausal symptoms would clearly unmask the treatment 
and control groups. 
Supporting evidence on estrogen’s benefits in primary, but not secondary, prevention of CHD 
comes from studies in monkeys: primary prevention resulted in 70% decrease in coronary 
artery atherosclerosis, whereas HRT initiated at 2 years after the menopause was ineffective 
(Williams et al. 1995, Adams et al. 1997, Clarkson et al. 1998, Clarkson et al. 2001). The 
failure to show any cardiovascular benefits in the randomized clinical trials has also been 
claimed to be due to several other factors besides the timing of the treatment, such as the type 
of estrogen used (CEE vs. estradiol), the route of administration (oral vs. transdermal), or the 
impact of progestin. In vitro, estrone, estriol and estrone sulfate, which constitute a major part 
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of CEE, have little or no inhibitory effects on vascular SMC proliferation, migration, and 
MAP kinase activity, whereas estradiol is effective (Dubey et al. 2000). It has also been 
reported that transdermal estrogen may reduce serum triglycerides and leave CRP levels 
unchanged, contrary to oral treatment (Crook et al. 1992, Strandberg et al. 2003). The data on 
whether progestins, and particularly MPA, interfere with estrogen’s vascular effects are 
controversial: some claim that progesterone is detrimental whereas others find no effect 
(Adams et al. 1990, Williams et al. 1994, Grodstein et al. 1996, Levine et al. 1996, Adams et 
al. 1997, Miyagawa et al. 1997, Gerhard et al. 1998, Grodstein et al. 2000, Kawano et al. 
2001). It has been suggested that other progestins, such as norethisterone, are more favourable 
than MPA on estrogen’s vasculoprotective functions and may even enhance them 
(Alexandersen et al. 1998, Ylikorkala et al. 2000). 
This thesis supports the clinical evidence on estrogen’s benefits in the primary prevention of 
vasculoproliferative disorders. Estradiol treatment right after surgical menopause significantly 
inhibited neointimal thickening in the rat. Moreover, the vasculoprotective effects of estrogen, 
or SERMs, were sustained when the treatment was discontinued on day 14, i.e. no rebound 
effect was observed. This suggests that the critical time interval in the development of intimal 
hyperplasia is before day 14, and supports the benefit of early treatment (III). Indeed, in the 
injured rat vessel, the protective responses occur rather early after injury: proliferation peaks at 
3 days in the media, at 4 days in the adventitia, and at 7 days in the neointima; and the 
responses gradually subside to a low level after 14 days post-injury (Du Toit et al. 2001, 
Frosen et al. 2001). Also, our more recent preliminary findings suggest that the vascular 
precursor cell influx peaks at 2-4 days post-injury and falls to a low level after 14 days (Luoto 
NM et al., unpublished results). Although the impact of delayed treatment on neointimal 
hyperplasia was not studied here, our findings may explain why the studies on the role of 
estrogen in the secondary prevention of cardiovascular disease failed; the treatment was 
initiated too late. 
6. Estrogen receptors as targets for vasculoselective drug therapy 
Attempts to target single genes in order to prevent vasculoproliferative disorders are usually 
not sufficient because other pathways remain active. Estrogens are tempting candidates for 
vasculoselective drug therapy as they are capable of regulating multiple genes at the same 
time. As the risks and advantages of HRT are debated, the development of tissue-selective 
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estrogens has become of interest. The potential alternatives today are SERMs, ERα/ERβ-
selective ligands, and phytoestrogens. An ideal compound would have beneficial effects on 
menopausal symptoms, cardiovascular system, bone, and brain, while being neutral in its 
effects on uterus and the breast, and carrying no risk for venous thromboembolism (Table 5). 
The absence of gender-related side-effects might make it applicable to men. Unfortunately, no 
such compounds are known today.  
Tamoxifen and raloxifene have favourable effects on plasma lipids, breast and bone but they 
do not alleviate menopausal symptoms. Ospemifene has no adverse effects on post-
menopausal symptoms, is neutral in its effects on hot flashes, and furthermore, has an 
estrogenic effect on vagina (Voipio et al. 2002, Rutanen et al. 2003). Previous studies have 
mainly concentrated on the effects of SERMs on lipid-induced changes in the arteries. This 
study shows the potential of the clinically used (tamoxifen and raloxifene) and two novel 
(ospemifene and fispemifene) SERMs to preserve estrogenic effects on the vascular injury 
response in the rat, i.e. the inhibition of SMC proliferation and migration as well as the 
enhancement of reendothelialization (III). It was notable that at least in the rat, the 
vasculoprotective doses were higher than the clinically used ones, which suggests that the 
current clinical dosing is incapable of achieving maximal vasculoprotection. Also the in vitro 
doses were over the physiological estradiol serum levels – however, serum estradiol 
concentrations may not be equal to tissue concentrations, since local estrogen synthesis may 
play a role also in the vasculature (Murakami et al. 2001). 
ERβ-selective compounds have now become available (Meyers et al. 2001, Harris et al. 2003). 
Their effects on the vascular wall are not yet known. Current data strongly suggest that ERβ is 
an important regulator of SMC biology after vascular injury and does not induce uterine 
growth (I, II), which makes ERβ-selective ligands potential candidates for vasculo-selective 
drug design. Furthermore, the predominant expression of ERβ in the inflammatory cells of the 
cardiac allografts (II), and the anti-inflammatory action of ERβ-selective ligands (Harris et al. 
2003), as well as the finding that ERβ-/- mice develop a myeloproliferative disease resembling 
human chronic myeloid leukemia with lymphoid blast crisis (Shim et al. 2003), suggest that 
ERβ-selective ligands might also have a potential therapeutic role in the prevention of immune 
activation after transplantation, and the subsequent development of transplant arteriosclerosis, 
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i.e. both as immunoregulatory and as vasculoprotective therapy. This merits further 
investigation.   
Table 5. Comparison between the effects of HRT, SERMs, and ER-selective ligands in different tissues 
 Vascular  Lipids Bone Breast  Uterus Vagina Hot  References 
 SMC EC   (ca)   flushes  
          
HRT - + - + + + + - MacGregor and Jordan 1998, 
Morello et al. 2002 
Tamoxifen - + - + - + - + MacGregor and Jordan 1998, 
Morello et al. 2002; III 
Raloxifene - + - + - 0 - + MacGregor and Jordan 1998, 
Morello et al. 2002; III 
Ospemifene - + - + - 0 + 0 Morello et al. 2002; III 
Fispemifene - + - + - 0 ? ? Lauri Kangas, personal 
communication; III 
ERα-agonist 0? +? - +* +* +* ? -* *Harris et al. 2002 
ERβ- agonist -? 0? ? 0* 0* 0* ? ? *Harris et al. 2003 
Ideal SERM - + - + - 0 + -  
          
66  
CONCLUSIONS AND SUMMARY 
The development of a hyperplastic neointima in restenosis and in allograft arteriosclerosis is a 
protective response to mechanical, immunological, or infectious injury to the vascular wall. 
The pathogenesis of these disorders resembles, in many respects, those of common 
atherosclerosis, including inflammation, influx of proliferating SMC to the injury site, 
extracellular matrix synthesis, and finally, vessel remodelling (Fig. 11). Furthermore, the 
current data suggest that neointimal SMC-like cells derive mainly, not from the vascular 
media, but from circulating precursor cells. Estrogen’s beneficial effects in the primary 
prevention of cardiovascular disease are well-established. However, estrogen therapy alone 
has some important side-effects, such as the growth-promoting effects in the uterus and breast. 
The data in this thesis support estrogen’s role in vasculoprotection; particularly in preventing 
the proliferation and migration of SMC to the injured artery, and the subsequent neointima 
formation. Estrogen receptor β is the predominant receptor in the vascular wall after 
mechanical and immunological injury, colocalizing with the vascular SMC in the media and 
neointima, while ERα remains at a low level only (Fig. 11). ERβ also predominates in the 
arteries, veins, myocardium, and inflammatory cells of cardiac allografts, but shows no 
correlation to the intensity of rejection. Furthermore, this study shows for the first time, that 
the vasculoprotective effects of estrogen can be differentiated from its uterotrophic effects 
with specific targeting to ERβ. The findings make ERβ a potential candidate for estrogen-
based vasculoselective drug design. SERMs bind both ERs with variable affinities, and have a 
mixed estrogen agonist/antagonist profile in different tissues. This study shows that some 
SERMs have beneficial estrogen agonist effects on the developing neointima after balloon 
injury, while being neutral or weakly estrogenic in the uterus. In addition, the study supports 
the hypothesis that early intervention of the injury-response is of paramount importance, and 
in some cases even sufficient to repress the response. Finally, estrogen interacts with growth 
factor signalling cascades, also in the vascular wall. It simultaneously inhibits the expression 
of IGF-1, PDGF, and PDGF-Rα mRNA and protein, and the concomitant proliferation and 
migration of vascular SMC, which is possibly one mechanism behind estrogen’s 
vasculoprotective properties (Fig. 11).  
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Figure 11. Potential targets of estrogen action in the development of vascular intimal hyperplasia. Whether the 
endothelial injury is mechanical, infectious, or alloimmune in origin, it initially leads to an inflammatory 
response. The injured endothelium expresses numerous proinflammatory molecules and adhesion molecules, 
which mediate the entry of the inflammatory cells to the vessel wall. The activated inflammatory cells replicate 
and secrete cytokines, which, in turn, stimulate endothelial cells (EC) and vascular smooth muscle cells (SMC). 
SMC migration and proliferation within the arterial intima is induced by growth factors and vasoactive peptides 
released from the activated leukocytes, and SMC themselves, which leads to persistent paracrine and autocrine 
proliferation. Vascular precursor cells are thought to contribute significantly to the development of neointimal 
hyperplasia. Estrogen therapy downregulates adhesion molecules, several proinflammatory cytokines, major 
histocompatibility (MHC) antigens, growth factors, and extracellular matrix (ECM) synthesis in the vascular 
wall. In addition, it increases the activity of nitric oxide synthase (NOS) and prostacyclin synthase, which results 
in vasodilation. Finally, estrogen receptors interact with growth factor signalling cascades. Estrogen receptor 
(ER) β is the predominant estrogen receptor in vascular SMC, and thus may primarily mediate the 
vasculoprotective actions of estrogen. ET-1; endothelin. 
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YHTEENVETO (FINNISH SUMMARY) 
Valtimon sisimmän kerroksen, intiman, paksuuntuminen ja siitä johtuva suonen 
umpeutuminen on tyypillinen muutos valtimonkovettumataudissa (ateroskleroosi) sekä 
sepelvaltimoiden pallolaajennuksen jälkeisessä uudelleenahtautumisessa (restenoosi). 
Immunosuppressiivisen lääkityksen kehittyminen on parantanut elinsiirtojen 
lyhytaikaisennustetta. Krooninen rejektio, jonka keskeinen manifestaatio on siirteen 
valtimoiden arterioskleroosi, on kuitenkin edelleen tärkein syy elinsiirteiden menetykseen. 
Lisäksi noin puolet siirteistä menetetään toimivina, pääasiassa kardiovaskulaaritapahtumien 
vuoksi.  
Edellä mainittujen tautien patofysiologialle on ominaista verisuonen sisäpintaa suojaavan 
endoteelikerroksen vaurio, joka johtaa verisuonen seinämän tulehdusreaktioon, 
sileälihassolujen kerääntymiseen vauriokohtaan sekä niiden jakautumiseen (proliferaatio) ja 
vaeltamiseen (migraatio) suonen seinämässä, valtimon seinämän paksuuntumiseen ja 
uudelleenmuotoutumiseen. Tärkeässä asemassa ovat erilaiset kasvutekijät ja sytokiinit, joita 
mm. verisuonen endoteelisolut, sileälihassolut ja tulehdussolut erittävät. Viimeaikaiset 
tutkimukset viittaavat lisäksi siihen, että paksuuntuneen neointiman muodostavat 
sileälihassolun kaltaiset solut ovat peräisin verenkierron kantasoluista, eivät verisuonen 
keskikerroksesta, mediasta, kuten aikaisemmin uskottiin.    
Estrogeeni on steroidihormoni, joka säätelee solujen jakautumista ja erilaistumista elimistön 
eri osissa. Estrogeenin verisuonia suojeleva vaikutus on osoitettu laajalti sepelvaltimotaudin 
ehkäisyssä ja tutkimukset eri eläinmalleissa ja soluviljelmissä tukevat vahvasti tätä havaintoa, 
vaikka viimeaikaisten seurantatutkimusten tulokset ovatkin olleet päinvastaisia. Huomattava 
estrogeenin sivuvaikutus on kuitenkin sen vaikutus kohtuun: estrogeenihoito lisää kohdun 
limakalvon syöpäriskiä ja voi nopeuttaa rintasyövän etenemistä. Aikaisemmin oli vaikea 
ymmärtää, miten estrogeenihoito voi samanaikaisesti stimuloida solujen jakautumista 
joissakin kudoksissa ja estää sitä toisaalla. Toisen estrogeenireseptorin (ER), ERβ:n, 
löytyminen ’klassisen’ ERα:n rinnalle lisäsikin merkittävästi ymmärrystämme estrogeenin 
vaikutusmekanismeista eri kudoksissa. 
Tämän väitöskirjatyön tavoitteena oli tutkia eri estrogeenireseptoreiden ilmenemistä 
pallolaajennuksen tai siirteen hyljintäreaktion aiheuttamassa verisuonen umpeutumisessa sekä 
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selvittää mahdollisia mekanismeja estrogeenin verisuonivaikutusten taustalla, keskittyen 
erityisesti verisuonen sileälihassolujen säätelyyn. Tavoitteena oli myös estää valtimon 
seinämän paksuuntumista estrogeenireseptoreihin eri tavoin sitoutuvilla aineilla. Työssä 
käytettiin rotan kaulavaltimon ja aortan pallolaajennusmalleja sekä rotan ja ihmisen 
sydänsiirtonäytteitä. Sileälihassolu- ja kudosviljelmissä tutkittiin estrogeenien vaikutusta 
solujen migraatioon ja proliferaatioon.  
Tämän tutkimuksen tulokset tukevat teoriaa, jonka mukaan estrogeenilla on merkittäviä 
verisuonia suojaavia ominaisuuksia: estrogeeni estää annosriippuvaisesti verisuonen 
sileälihassolujen proliferaatiota ja migraatiota sekä paksuuntuneen intiman muodostumista (I, 
III, IV). Tutkimus osoittaa, että ERβ on vallitseva reseptori valtimon seinämän 
sileälihassoluissa verisuonivaurion jälkeen, kun taas ERα ilmenee ainoastaan matalalla tasolla 
(I). ERβ ilmenee voimakkaasti myös sydänsiirteen valtimoissa, laskimoissa, sydänlihaksessa 
ja tulehdussoluissa (II). Estrogeenin hyödylliset verisuonivaikutukset voidaan lisäksi erottaa 
sen haitallisista kohtua kasvattavista vaikutuksista aineilla, jotka sitoutuvat voimakkaasti 
ERβ:aan (I). Nämä havainnot tekevät ERβ:sta potentiaalisen verisuoniselektiivisen 
lääkesuunnittelun kohteen. 
Selektiiviset estrogeenireseptorin säätelijät (SERM) sitoutuvat molempiin 
estrogeenireseptoreihin eri voimakkuuksilla ja vaikuttavat estrogeenin tavoin tietyissä 
kudoksissa ja antiestrogeenin tavoin toisissa kudoksissa. Tämä työ osoittaa, että osa SERM:sta 
estää pallolaajennuksen jälkeistä restenoosia estrogeenin tavoin stimuloimatta kohdun kasvua 
(III). Verisuonivaurion aiheuttamien vasteiden esto välittömästi vaurion jälkeen on erityisen 
tärkeää, kun taas pitkään jatkuvalla hoidolla on vähemmän merkitystä. 
Väitöskirja osoittaa lisäksi, että estrogeenihoito vähentää eri kasvutekijöiden ilmenemistä 
verisuonen seinämässä mekaanisen vaurion (pallolaajennus) jälkeen (IV). Se estää insuliinin 
kaltaisen kasvutekijän (IGF-1), verihiutaleperäisen kasvutekijän (PDGF) sekä PDGF-reseptori 
α:n muodostumista verisuonessa, mikä on mahdollisesti yksi tärkeä mekanismi estrogeenin 
hyödyllisten verisuonivaikutusten taustalla.   
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SAMMANDRAG (SWEDISH SUMMARY) 
Förtjockning av artärens innersta lager, intiman, och därav förorsakad förträngning av 
blodkärlet är en typisk förändring vid blodkärlsförkalkning (ateroskleros) och återförträngning 
av kransarterärna efter ballong-dilatation (restenos). Framsteg i utvecklingen av 
immunosuppressiv medicinering har förbättrat transplantationers korttidsprognos. Kronisk 
rejektion, vars centrala manifestation är arterioskleros i det transplanterade organets artärer, är 
dock fortfarande den viktigaste orsaken till att transplantat trots allt förloras. Kring hälften av 
transplantaten förloras därtill funktionsdugliga, främst på grund av kardiovaskulära händelser. 
Typiskt för ovan nämnda sjukdomars patofysiologi är en skada på endotellagret som skyddar 
blodkärlens insida. Skadan orsakar en inflammationsreaktion i blodkärlsväggen samt en 
ansamling av glatta muskelceller vid skadan och deras proliferation och migration inom 
blodkärlsväggen, och slutligen, en förtjockning och omformning av artärväggen. Olika 
tillväxtfaktorer och cytokiner, vilka utsöndras av bland annat blodkärlens endotelceller, glatta 
muskelceller och inflammationsceller, spelar en viktig roll i processen. Därtill har nyligen 
publicerade undersökningar påvisat, att de glatta muskelcellsliknande celler som bygger upp 
den förtjockade neointiman kunde härstamma från stamceller i blodcirkulationen och inte från 
blodkärlets mellanlager, median, så som man tidigare trott. 
Estrogenet är ett steroidhormon som reglerar celldelning och -differentiering i olika delar av 
kroppen. Estrogenets blodkärlsskyddande effect har påvisats vitt i primarprevention av 
ateroskleros, och undersökningar i olika djurmodeller och cellexperiment stöder fynden, trots 
att det på senaste tid publicerats rapporter med motsatta resultat. Estrogenets betydande 
bieffekt är dess effekt på livmodern: estrogenterapin ökar risken för cancer i 
livmoderslemhinnan och kan försnabba progressionen av bröstcancer. Tidigare var det svårt 
att förstå hur estrogenterapi samtidigt kan stimulera celldelning i vissa vävnader och samtidigt 
hindra den på andra håll. Dock ökade upptäckten av den andra estrogenreceptorn (ER)β, vid 
sidan om den ’klassiska’ ERα, avsevärt vår insikt i estrogenets verkningsmekanismer i olika 
vävnader.  
Målet med detta avhandlingsarbete var att undersöka förekomsten av olika estrogenreceptorer 
i blodkärlsförtjockning efter ballongdilatation eller transplantationsrejektion, samt att utreda 
möjliga mekanismer bakom estrogenets blodkärlsverkan, med betoning på regleringen av 
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blodkärlens glatta muskelceller. Målet var också att hindra artärväggens förtjockning med 
ämnen som binder sig olika till de två estrogenreceptorerna. I arbetet användes 
ballongdilatationsmodeller på råttors halsartär och aorta, samt prover från råttors och 
människors hjärttransplantat. Estrogenernas verkan på cellmigration och -proliferation 
undersöktes med cell- och vävnadsodlingar.  
Undersökningsresultaten i denna avhandling stöder teorin enligt vilken estrogenet har 
betydande blodkärlsskyddande egenskaper: estrogenet hämmar dosrelaterat proliferation och 
migration av blodkärlens glatta muskelceller, samt en förtjockning av intiman. (I, III, IV). 
Undersökningarna påvisar även att ERβ är den dominerande receptorn i artärväggens glatta 
muskelceller efter blodkärlsskada, medan ERα endast förekommer i låga nivåer (I). 
Förekomsten av ERβ är stor även i artärer, vener, hjärtmuskel och inflammationsceller i 
hjärttransplantat (II). Estrogenets nyttiga blodkärlseffekter kan dessutom åtskiljas från dess 
skadliga effekter på livmodern med ämnen som binder kraftigt vid ERβ (I). Dessa fynd gör 
ERβ till ett potientiellt mål för blodkärlsselektiv läkemedelsdesign.  
Selektiva estrogenreceptormodulatorer (SERM) binder till båda estrogenreceptorer med olika 
affinitet och verkar estrogenlikt i vissa vävnader och antiestrogenlikt i andra vävnader. Det här 
arbete påvisar, att en del av SERM hämmar restenos efter ballongdilatation liksom estrogen, 
utan att stimulera tillväxten av livmodern (III). Viktigt är att kunna hämma blodkärlsskadans 
effekter omedelbart efter skadan, långtidsterapihar en mindre betydelse. 
Avhandlingen påvisar även att estrogenbehandling minskar förekomsten av olika 
tillväxtfaktorer i blodkärlsväggen efter mekanisk skada vid ballongdilatation (IV). 
Estrogenbehandlingen hindrar bildandet av insulinlik tillväxtfaktor 1 (IGF-1), 
trombocytderiverad tillväxtfaktor (PDGF) och PDGF-reseptor α i blodkärlen, vilket kan vara 
en viktig mekanism bakom estrogenets  blodkärlsskyddande effekt.  
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